Cardiac magnetic resonance in catheter ablation of atrial arrhythmias:characterisation of substrate and guidance of therapy by Harrison, James Lloyd
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Cardiac magnetic resonance in catheter ablation of atrial arrhythmias




Download date: 06. Nov. 2017
 
Cardiac magnetic resonance  
in catheter ablation of atrial 
arrhythmias: characterisation of 
















A dissertation submitted for the degree of 
 
Doctor of Philosophy 
 
Division of Imaging Sciences and Biomedical Engineering 
School of Medicine 
King’s College London 



















For Oliver  
 3 
Abstract 
Cardiac magnetic resonance (CMR) imaging has been recently used to provide non-
invasive tissue characterisation before and after catheter ablation of atrial 
arrhythmias and to guide real-time electrophysiology procedures within the CMR 
environment. This thesis develops and validates new CMR techniques for use at 
the interface between cardiac imaging and interventional electrophysiology using 
both pre-clinical animal and clinical human studies. There are three main 
objectives: 
1) Whilst the use of CMR to characterise acute and chronic ventricular myocardial 
injury only became clinically accepted and in widespread use following 
comprehensive pathological validation, there has been no fundamental validation 
work on the CMR assessment of the atrium. This thesis provides the first 
comprehensive histological validation of CMR and electroanatomical mapping (EAM) 
of acute and chronic ablation injury in a new animal model of atrial ablation. 
2) Previous studies have suggested a qualitative and quantitative relationship 
between atrial CMR findings and endocardial voltage. However, there is conflicting 
evidence regarding the reproducibility and diagnostic accuracy of atrial CMR as a 
surrogate for electrical disease. This thesis compares atrial CMR findings with 
endocardial voltage mapping in patients undergoing repeat catheter ablation for left 
atrial (LA) arrhythmias and assesses the ability of atrial CMR to predict gaps in 
ablation lesions. 
3) The final objective of the thesis is to assess the feasibility of a real-time magnetic 
resonance-guided electrophysiology (MR-EP) system in an animal model of atrial 
ablation. MR-EP offers several potential advantages over x-ray fluoroscopy and 
conventional EAM systems. It provides rapid, high resolution, 3D visualisation of 
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the true anatomy and endocardial surface of the cardiac chambers with unrivalled 
soft tissue contrast, the potential to visualise ablation lesions and acute 
complications with high spatial resolution, and raises the possibility of eliminating 
patient and physician exposure to ionising radiation. This thesis demonstrates, for 
the first time, the feasibility of using an actively-tracked radiofrequency (RF) 
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The aim of this thesis is to evaluate the role of CMR in the characterisation of atrial 
ablation injury in a controlled animal model, applying these findings to a clinical 
study of patients undergoing repeat catheter ablation for atrial arrhythmias, and to 
develop an integrative approach between CMR and interventional cardiac 
electrophysiology. The thesis is organised as follows: 
SECTION ONE: BACKGROUND AND LITERATURE REVIEW 
Chapter 1 introduces the mechanism, classification and current treatment of atrial 
arrhythmias. 
Chapter 2 discusses the methodology of atrial CMR, including its use before and 
after catheter ablation for atrial fibrillation (AF) and its role in defining atrial 
anatomy, volume and function. 
Chapter 3 provides a short introduction to the physical principles of atrial CMR, 
including a description of MR signal generation and encoding, and the main pulse 
sequences used in atrial CMR. 
Chapter 4 describes how the principles from Chapters 1, 2 and 3 can be applied to 
real-time MR-EP. 
SECTION TWO: METHODS AND EXPERIMENTAL DATA 
Chapter 5 presents the methods used for Chapters 6, 7 and 8. 
Chapter 6 provides a comprehensive histological validation of CMR and EAM of 
acute and chronic ablation injury in a new animal model of atrial ablation. 
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Chapter 7 compares atrial CMR findings with endocardial voltage mapping in 
patients undergoing repeat catheter ablation for LA arrhythmias and assesses the 
ability of atrial CMR to predict gaps in ablation lesions. 
Chapter 8 demonstrates the feasibility of using an actively-tracked RF ablation 
catheter within a fully MR-compatible EP system as a prelude to a planned human 
study. 
Chapter 9 concludes the thesis by discussing the original contributions, 
















1 Atrial arrhythmias 
1.1 Introduction 
The aim of this thesis is to develop and validate CMR techniques, which have the 
potential to improve catheter ablation therapy for atrial arrhythmias (atrial 
tachycardia (AT), atrial flutter and AF). This chapter provides an overview of the 
current classification and treatment of atrial arrhythmias.  
1.2 Atrial tachycardia 
Atrial tachycardia was originally classified exclusively based on the ECG 
appearances as an arrhythmia of atrial origin with a ventricular rate below 240-
250 beats per minute, a regular P wave activity and an isoelectric baseline between 
P waves, except in atrial flutter.1 However, with an improved understanding of 
arrhythmia mechanism through the development of sophisticated interventional 
techniques, it became clear that this classification correlated poorly with the 
underlying tachycardia mechanism and substrate, and so a mechanistic 
classification was necessary. A consensus statement from a Joint Expert Group 
from the Working Group of Arrhythmias of the European Society of Cardiology and 
the North American Society of Pacing and Electrophysiology classified AT as either 
focal or macroreentrant, which is now widely adopted.2 Focal ATs are 
characterised by a single site (focus) of origin with centrifugal spread of electrical 
activation from this point. The underlying mechanism may be abnormal 
automaticity, triggered activity or microreentry. Macroreentrant ATs involve a 
large (typically greater than 2 cm) circuit within the atrium around a central 
obstacle, which may be anatomical (e.g. pulmonary veins (PVs), mitral or tricuspid 
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annulus, surgical or spontaneous scar) or an area of functional block (e.g. crista 
terminalis). They have no point of origin, are characterised by a site of ‘early-
meets-late’ activation and include typical or reverse typical (cavotricuspid 
isthmus-dependent) atrial flutter and atypical right atrial (RA) and LA flutters. 
Since this classification, a third mechanistic category, localised reentry, has been 
described, involving reentrant circuits less than 2 cm in size and most commonly 
seen following extensive substrate modification during catheter ablation for 
persistent AF.3 
1.2.1 Focal AT 
Focal ATs are responsible for approximately 10% of all supraventricular 
tachycardias4 and occur most commonly in the absence of structural heart 
disease,5 but can be associated with low voltage atrial tissue.6 Typically, the ECG 
shows discrete P-waves with an intervening isoelectric baseline, but this can be 
obscured by a rapid ventricular response rate. Focal ATs often demonstrate a 
gradual increase in rate at onset (“warm-up”) and a gradual decrease in rate at 
offset (“cool-down”), unlike macroreentrant ATs, which tend to have sudden 
initiation and termination. The sites of focal ATs are not randomly distributed, 
with a predilection for the RA, particularly certain anatomical structures, including 
the crista terminals, tricuspid annulus, coronary sinus (CS) os, superior vena cava 
(SVC) and RA appendage. As a result, algorithms based on the ECG P-wave 
morphology have been described to localise the focus prior to catheter ablation, 
with a positive and negative P-wave in lead V1 suggesting an LA and RA focus 
respectively.7, 8 
First-line therapy is pharmacological, using cardioselective beta-blockers or non-
dihydropyridine calcium channel blockers for rate control or Class Ic (e.g. 
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flecainide or propafenone) or Class III (e.g. sotalol or amiodarone) 
antiarrhythmics. However, all of these have relatively poor efficacy and are 
associated with significant side effects. As a result, the past two decades have seen 
a significant increase in the use of catheter ablation to treat focal ATs, and this is 
now considered first-line therapy for those with recurrent or incessant tachycardia 
of tachycardia-induced cardiomyopathy.9 
Catheter ablation for focal AT requires the presence of sustained tachycardia or 
frequent ectopy in order to find the site of earliest atrial activation. This is often 
aided by a 3D EAM system to produce a colour-coded isochronal activation map, 
with the characteristic pattern of a central point of activation with radial 
propagation. Ablation, most commonly RF energy, is applied to the focus with an 
acute success rate of 85-90%.10 Complications and recurrence are rare11 and 
patients presenting with tachycardia-induced cardiomyopathy generally show 
good recovery of left ventricular (LV) function following successful ablation.12 
1.2.2 Macroreentrant AT 
1.2.2.1 Typical atrial flutter 
Typical (cavotricuspid isthmus-dependent) atrial flutter was the first 
macroreentrant AT treated with catheter ablation, based on an understanding of 
the arrhythmia mechanism.13 The reentrant circuit is well defined, with an anterior 
boundary of the tricuspid annulus and a posterior boundary of the crista 
terminalis (a functional barrier to transverse conduction in the RA due to tissue 
anisotropy) and the Eustachian ridge.14 Septal activation of the RA is from inferior 
to superior, whilst activation of the lateral wall of the RA is in the opposite 
direction. Activation around the tricuspid annulus is in an anticlockwise direction 
in most cases (resulting in the classical sawtooth ECG pattern in the inferior leads), 
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but is clockwise (reverse typical) in 10% of patients.15 The cavotricuspid isthmus, 
a body of fibrous tissue in the lower RA between the inferior vena cava (IVC) and 
the tricuspid valve, is an integral part of the circuit and is the preferred target for 
catheter ablation as it is narrow and provides a safe and stable catheter position 
for the delivery of a linear ablation lesion. 
Typical atrial flutter may occur in the absence of structural heart disease (“lone”) 
or with concomitant ischaemic heart disease, valvular heart disease, 
cardiomyopathy or any cause of increased RA pressure. Its prevalence increases 
with age and is more common in males than females.16 It may present in many 
different ways: paroxysmal or persistent palpitations, syncope (particularly if 
there is 1:1 atrial to ventricular conduction), silently (as an incidental finding), 
transient ischaemic attack or cerebrovascular accident, a tachycardia-induced 
cardiomyopathy or pre-syncope/syncope due to sinus node disease as part of the 
bradycardia-tachycardia syndrome. Furthermore, patients with typical atrial 
flutter are predisposed to the later development of AF (in over 30% of cases17) and 
guidelines suggest that thromboprophylaxis in patients with atrial flutter should 
follow the same guidance as for AF.18 
Catheter ablation targeting the critical (cavotricuspid) isthmus was first shown to 
terminate the tachycardia and prevent reinduction in the early 1990s13, 19 and is 
now considered first-line therapy for typical atrial flutter due to the high efficacy, 
low complication rates and the relative ineffectiveness of pharmacotherapy. A 
randomised controlled trial of antiarrhythmic medication versus first-line RF 
ablation in 61 patients showed that after a mean follow-up of 21 ± 11 months, 36% 
of patients receiving drugs were in sinus rhythm, whilst 80% of patients who 
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underwent ablation were in sinus rhythm (p<0.01).20 Furthermore, there were 
more hospitalisations in the group receiving drugs. 
In early studies, the endpoint of ablation was tachycardia termination and an 
inability to reinduce tachycardia. However, this resulted in frequent recurrence of 
atrial flutter13 and contemporary practice uses the endpoint of bidirectional 
conduction block across the cavotricuspid isthmus. This is demonstrated using 
differential pacing techniques and is associated with a less than 5% flutter 
recurrence  rate.21 An additional endpoint is the presence of double potentials with 
an interpotential interval of greater than 110 ms.22    
In a survey of multiple centres, the results for 7,071 patients who had undergone 
catheter ablation for typical atrial flutter were pooled.21 A repeat ablation 
procedure was performed in 4% of patients, and the long-term success rate was 
97%. The overall incidence of serious complications was 0.4%, with the most 
common complication being atrioventricular block in 0.2% of patients. In a meta-
analysis of 1,323 patients, single and multiple procedure success rates were 92% 
and 97% respectively and repeat ablation was necessary in 8% of patients.23 
1.2.2.2 Atypical atrial flutter 
This term encompasses all macroreentrant ATs except cavotricuspid-isthmus 
dependent atrial flutter. They can occur in patients with no previous atrial surgery 
with circuits around areas of spontaneous LA or RA fibrosis. In these patients, the 
circuit may involve the lateral RA wall, lower loop reentry around the IVC or single 
or dual LA circuits (around the PVs and/or mitral annulus) associated with LA 
enlargement (e.g. heart failure, mitral regurgitation). With LA enlargement, fibrosis 
may develop, providing an obstacle that permits and stabilises reentry. One study 
reported eight patients with macroreentrant AT related to a zone of spontaneous 
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scar in the posterolateral RA,24 whilst another described de novo LA 
macroreentrant tachycardias associated with areas of reduced or absent voltage, 
particularly on the posterior LA wall.25  
More commonly, atypical AT occur in patients with previous atrial surgery or 
ablation, around surgical scars, suture lines or prosthetic patches following 
surgical correction of congenital heart disease (lesional AT) or around scar formed 
by surgical or catheter ablation for AF. Whilst uncommon following PV isolation for 
paroxysmal AF, left ATs are increasingly seen (in up to 50% of cases26) following 
extensive LA ablation for persistent AF, involving the formation of linear ablation 
lesions and targeting of complex fractionated atrial electrograms (substrate 
modification). Gaps in these linear ablation lesions permit macroreentry, most 
commonly around the LA roof, the mitral annulus or PVs. The circuits can be 
complex, not infrequently involving dual loops, whereby ablation of one unmasks 
the other. The P wave characteristics of atypical atrial flutters are highly variable 
and rarely provide clues as to the location or circuit. Drug therapy is rarely 
effective and catheter ablation is indicated with recurrent or poorly tolerated 
symptoms. 
Catheter ablation of atypical macroreentrant AT is often complex and most 
commonly involves the use of 3D EAM, which permits the integration of complex 
anatomy with endocardial voltage to identify areas of scar, activation mapping to 
determine the direction of propagation and entrainment values to define sites that 
are within or outside of the circuit. As with all macroreentrant tachycardias, there 
is no site of origin, but there is a site of ‘early-meets-late’ activation and it is 
normally possible to map a large percentage of the tachycardia cycle length (unlike 
focal tachycardias, in which only a small percentage of the tachycardia cycle length 
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can be mapped, the rest coinciding with the isoelectric interval). Mapping may 
demonstrate lines of functional block, which can act as a substrate for 
macroreentry, with double potentials resulting from activation either side of the 
line. Ablation success requires identification of an anatomical or functional 
isthmus critical to the macroreentrant circuit, which can be interrupted with a 
linear or focal ablation lesion. As a result of the complex circuits involved, success 
rates are more modest compared with ablation of typical atrial flutter. Success is 
variable, with better results in patients with simpler previous surgery or catheter 
ablation than those who have had more complex congenital heart disease repairs.  
1.2.2.3 Localised reentry 
Also known as “small circuit reentry”, this has been increasingly recognised in the 
past few years, and is most commonly seen following extensive substrate 
modification during catheter ablation for persistent AF.3, 27, 28 The circuits are 
smaller than macroreentry, typically 1-2 cm in size. In a study of 128 patients with 
previous catheter ablation for AF, there were a total of 246 ATs.3 Approximately 
half of these were macroreentrant, whilst of the non-macroreentrant tachycardias, 
only 25% were truly focal. The other three quarters involved a 1-2 cm circuit with 
greater than 75% of the tachycardia cycle length mappable. It is unknown whether 
these localised reentrant circuits are drivers for AF or whether they are just the 
result of previous ablation.  
1.3 Atrial fibrillation  
AF is a supraventricular tachyarrhythmia characterised by uncoordinated atrial 
activation with consequent deterioration of atrial mechanical function.29 It is the 
most common cardiac arrhythmia, with an increasing prevalence with age. AF 
affects an estimated 2.2 million adults in the United States30 and each year around 
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46,000 people in the United Kingdom are newly diagnosed with the condition.31 It 
is a leading cause of stroke and with an increasingly elderly population, the 
prevalence of AF is set to rise, conferring substantial mortality, morbidity and 
economic burden. In the Framingham study, the presence of AF independently 
increased mortality in men by 1.5 fold and in women by 1.9 fold.32 Although the 
AFFIRM study demonstrated that rhythm control conferred no prognostic benefit 
when compared with rate control, a sub-study of this trial has shown that if sinus 
rhythm can be achieved without the use of anti-arrhythmic drugs, there is a 
substantial mortality benefit.33 Until recently, the mainstay of treatment for AF has 
been pharmacological but this is limited by concerns about efficacy, side effects 
and safety. 
1.3.1 Electrical remodelling in AF 
The natural history of AF is characterised by a gradual worsening over time, with 
an increasing frequency and/or duration of arrhythmia episodes. Eventually, the 
AF does not terminate and becomes persistent*. The finding that AF itself produces 
changes in atrial function and structure has provided a possible explanation for the 
progressive nature of AF. 
The concept of tachycardia-induced atrial electrical remodelling was introduced in 
1995 by two independent experimental studies.34, 35 In a dog model of prolonged 
rapid atrial pacing the atrial refractory period was reduced by about 15%. In goats, 
AF was maintained by implanting a pacemaker, which automatically delivered 
                                                        
*According to ACC/AHA/ESC guidelines: paroxysmal AF involves self-terminating episodes that last 
<7 days (usually <24 hours); persistent AF does not self-terminate; long-standing persistent AF is 
persistent AF for >1 year; permanent AF is where DC cardioversion does not terminate the 
arrhythmia (or is not attempted due to low anticipated chance of success). Lone AF is AF that 
occurs in young patients (<65 years) with structurally normal hearts and no evidence of other 
causative pathology (such as hypertension or diabetes). 
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bursts of atrial stimuli as soon as sinus rhythm occurred. This resulted in an even 
more marked shortening in atrial refractoriness from 146 ± 19 ms to 81 ± 22 ms 
after two to four days of AF and a loss (or even reversal) of the normal rate 
adaptation of the refractory period. More importantly, these studies showed that 
long-term rapid atrial pacing led to a progressive increase in the susceptibility to 
AF. After six weeks of rapid atrial pacing, episodes of AF lasting >15 min could be 
induced in 82% of the dogs. In ten out of 11 goats, after maintaining AF for 7.1 ± 
4.8 days, the arrhythmia sustained itself for >24 hours. In contrast, at the start of 
the experiment, episodes of AF induced by burst pacing only self-sustained for 
6 ± 3 s. This observation of tachycardia-induced electrical remodelling creating a 
substrate for persistent AF, led to the concept that “AF begets AF”.34 
1.3.2 Structural remodelling in AF 
In addition to electrical remodelling, structural remodelling, involving myocardial 
fibrosis (the most common histological feature of the failing heart) is a hallmark of, 
and fundamental to, the progression of AF.36, 37 Structural remodelling contributes 
synergistically with electrical remodelling to form the arrhythmogenic substrate in 
AF. There is an increase in atrial fibrosis, not only in patients with AF and 
underlying heart disease, but also in patients with lone AF38-41 and there is a 
positive correlation between the amount of fibrosis and the persistence of AF.41 
Even when the ventricular rate is controlled, rapid atrial activation in a dog causes 
atrial fibrosis,42 perhaps due to the secretion of chemokines by atrial myocytes, 
which enhance collagen synthesis by atrial fibroblasts.43 
Ventricular tachypacing induces congestive heart failure in dogs by causing a 
tachycardiomyopathy,44 and produces atrial interstitial fibrosis comparable with 
many forms of clinical AF.45 In the dog model, atrial fibrosis causes localised 
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regions of conduction slowing, increasing conduction heterogeneity and providing 
a substrate for AF.45 
1.3.3 Catheter ablation of paroxysmal AF 
In recent years, catheter ablation has emerged as an effective and potentially 
curative approach for patients with symptomatic paroxysmal AF. The 2012 Heart 
Rhythm Society, European Heart Rhythm Association and European Cardiac 
Arrhythmia Society consensus statement on catheter and surgical ablation of AF 
recommends catheter ablation as a reasonable first-line therapy for selected 
patients with paroxysmal AF.46 However, this is an expert consensus, which is not 
necessarily supported by clinical trials, and it is still common practice to try 
antiarrhythmic drug therapy before proceeding to catheter ablation. Furthermore, 
the consensus document specifies that catheter ablation should be performed in 
experienced high-volume centres by experienced operators to maximise success 
and minimise complications. In patients who are highly symptomatic, catheter 
ablation can improve quality of life,47 but as there is no randomised controlled trial 
demonstrating a reduction in stroke risk or mortality with catheter ablation, 
patients with no or minimal symptoms should be offered drug therapy for rate 
control. However, the Catheter Ablation versus Anti-arrhythmic Drug Therapy for 
Atrial Fibrillation (CABANA) Trial aims to answer this question in a prospective 
randomised multi-centre international study with a primary endpoint of all-cause 
mortality, and secondary endpoints of cardiovascular mortality and stroke. 
The demonstration that paroxysmal AF is frequently triggered by ectopy arising 
from within the PVs has led to the emergence of PV isolation as a widely practised 
therapy for this arrhythmia.48 In the early days of AF ablation, only spontaneously 
firing PVs were ablated. However, high recurrence rates, the increasing recognition 
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that all PVs can initiate AF and technological developments mean it is now routine 
practice to isolate all four PVs.49   
Pulmonary vein isolation (PVI) requires transseptal access to the LA and 
identification of the PV ostia, following which ablation lesions are deployed in a 
continuous and circumferential manner to isolate the left and right PVs, either 
individually or in pairs, with the endpoint of electrical disconnection from the LA. 
Incomplete or non-transmural circumferential ablation lesions may lead to 
immediate or delayed reconnection of the PVs, which can be documented in the 
majority of cases of AF recurrence.50   
One possible mechanism for reconnection is that the application of RF energy to 
the LA wall causes an acute inflammatory response. Tissue oedema during this 
inflammatory response may result in temporary electrical isolation of the PVs, but 
may prevent delivery of sufficient RF energy to cause tissue necrosis.51 Electrical 
reconnection between the LA and PVs occurs once the oedema has resolved. These 
gaps in ablation lines are thought to be one of the reasons for the relatively modest 
success rates of AF ablation – a meta-analysis suggested single and multiple 
procedure success rates (off antiarrhythmic drug therapy) of 57% and 71% 
respectively,52 whilst more recent studies have reported five-year success for 
multiple procedures in 80-92% of patients.53-55 
1.3.4 Catheter ablation of persistent AF 
The mechanisms responsible for persistent AF are less clear, and whilst PV foci 
may be involved in initiation of AF in a subset of patients, mechanisms involved in 
the maintenance of AF are most likely more important. Comorbidities including 
heart failure, hypertension, valvular heart disease and obstructive sleep apnoea 
are all responsible for electrical and structural remodeling of the LA with the 
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development of regional fibrosis, providing a substrate for persistent AF.56 Animal 
studies have shown the importance of atrial rotors in maintaining AF,57, 58 and 
recent human studies have suggested that ablation targeting these rotors may be 
able to terminate persistent AF. 59-61 
The uncertainty in the mechanisms involved in persistent AF has led to the 
development of many different empirical ablation strategies with often 
disappointing success.62 These strategies include PV isolation, linear ablation, 
substrate modification targeting complex fractionated atrial electrograms, ablation 
of autonomic ganglia, and isolation of the SVC and CS. Stepwise procedures 
involving two or more of these approaches have been described with evidence for 
a cumulative effect.63 However, these are based on unproven assumptions about 
the mechanism of AF, which contrasts with catheter ablation of AT and paroxysmal 
AF. A systematic review comparing multiple techniques in 32 studies suggested 
single procedure success rates of between 11% and 74% (mean 47%), increasing 
to 17% to 84% (mean 65%) with multiple procedures,62 confirming that the 
optimal ablation technique for persistent AF remains unclear. 
 
The next chapter discusses the role of CMR in providing non-invasive insights into 
the underlying substrate responsible for atrial arrhythmias and how CMR can be 
used both before and after catheter ablation procedures.  
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2 Atrial cardiac magnetic resonance 
2.1 Introduction 
Over the past two decades, CMR has evolved as a non-invasive imaging 
technique that allows comprehensive assessment of cardiac anatomy and 
function. More recently, late enhancement CMR using gadolinium-based 
contrast agents has enabled the imaging of myocardial tissue composition and 
therefore myocardial fibrosis. However, the overwhelming majority of CMR 
work has focused on the ventricles and it is only in the past few years that 
technical advancements in CMR have made late enhancement imaging of the 
thin atrial wall possible. In turn, the significant increase in catheter ablation for 
AF in the past decade has resulted in an increasing focus on CMR assessment of 
atrial structure and function and their potential link to arrhythmia substrate. 
2.2 Atrial late gadolinium enhancement 
2.2.1 Imaging myocardial fibrosis 
The first clinical application of myocardial LGE was in acute and chronic 
myocardial infarction64-66 and animal studies suggest a close correlation 
between areas of LGE in the ventricle and areas of scar on histology.67 During 
the chronic phase of infarction, when dense fibrotic scar replaces infarcted 
myocardium, it has been shown that LGE accurately and reproducibly 
determines infarct size.68 Furthermore, studies have shown the higher 
sensitivity for infarct detection by LGE compared with single-photon emission 
computed tomography.69, 70  
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Over the past ten years, many studies have been published assessing 
myocardial fibrosis by LGE in non-ischaemic cardiomyopathies. Different 
patterns of LGE have been demonstrated according to the underlying aetiology, 
and LGE CMR now forms an important assessment of new-onset myocardial 
dysfunction.68, 71, 72 
2.2.2 Limitations of late gadolinium enhancement 
LGE allows a sensitive and reproducible qualitative assessment of myocardial 
fibrosis, but is limited in its accuracy in quantifying myocardial fibrosis. In 
addition, the assessment of diffuse myocardial fibrosis is more challenging than 
discrete fibrosis due to the relatively lower image contrast. With conventional 
LGE imaging sequences, signal intensity (SI) is expressed on an arbitrary scale 
that differs from one imaging study to another and is not suitable for 
quantification between patients. Image contrast is generated by the difference 
in SI between normal and abnormal myocardium and, during post-processing, 
an arbitrary intensity threshold is defined to make this differentiation.73 There 
is no consensus on the intensity threshold to use for the clinical assessment of 
myocardial fibrosis and various methods have been described.73-76 This might 
explain why studies examining the same cardiomyopathy have reported 
significantly different frequencies of myocardial fibrosis and questions the 
reliability and reproducibility of LGE for myocardial fibrosis quantification in a 
clinical setting. To try and overcome this significant limitation of LGE imaging, 
this thesis explores the use of pathologically-validated SI thresholds to 
distinguish between normal and abnormal atrial myocardium. 
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2.2.3 Left atrial late gadolinium enhancement 
Atrial wall imaging poses a greater challenge than LV imaging since the wall of 
the LA is several times thinner than the LV myocardium, and, therefore, greater 
spatial resolution is required. Over the past few years, technological 
developments and novel imaging sequences have made LA LGE CMR possible.77, 
78 A recent series of studies has suggested that LA LGE both before and after 
catheter ablation can help predict the chance of recurrence of AF by identifying 
the extent of pre-existing fibrosis and post-ablation injury.51, 78-86 It has been 
proposed that this may allow a more individualised approach to AF ablation.  
Imaging sequences for LA LGE imaging begin with an anatomical scan for LA 
and PV segmentation. Fifteen to twenty minutes after the administration of a 
gadolinium-based contrast agent, 3D LGE imaging is performed with a 
respiratory-navigated, ECG-triggered acquisition with a typical in-plane spatial 
resolution of 1.3x1.3 mm2 and a slice thickness of 2.5-3 mm. The inversion time 
(TI) is determined using a preceding Look-Locker sequence to achieve optimal 
suppression of ventricular myocardium. The scan is typically acquired in an 
axial orientation, with 30-40 slices to achieve complete coverage of the LA. The 
length of the acquisition window is restricted to minimise motion artefacts. The 
two most important predictors of poor LA LGE image quality are the presence 
of AF (particularly with a rapid ventricular response rate) and an inconsistent 
respiratory navigator signal (Figure 2-1). 
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Figure 2-1: Examples of good (left) and poor (middle and right) image 
quality in 3D LA LGE acquisitions. 
 
2.2.3.1 Image processing 
This is one of the most challenging areas in LA LGE imaging and several 
methods have been suggested.77, 80, 87 Clinical interpretation of 2D images is 
extremely difficult given the complex anatomy, and 3D reconstructions have 
been employed in most publications to date. These require both an accurate 
segmentation of the LA and PVs, as well as the more challenging segmentation 
of the LGE information from the 2D slices and registration of this information to 
the reconstructed shell.  
In the LV, there is good image contrast between the healthy myocardium and 
areas of LGE. This is not the case in the much thinner-walled atrium, where it is 
more difficult to differentiate normal myocardium from areas of LGE, primarily 
due to greater susceptibility to image artefacts (motion and partial volume 
effect). 
The method used in this thesis (Figure 2-2)87 first involves image registration of 
the 2D information from the LGE scan to the b-SSFP whole heart acquisition. A 
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semi-automatic segmentation of the LA 3D anatomy from the b-SSFP whole 
heart acquisition is then performed and the registered 2D data is projected on 
to the 3D shell. Once fused, a maximum intensity projection (MIP) technique is 
used, whereby the maximum SI within ±3 mm of the 3D surface is selected as 
the intensity for that point on the shell. The MIP is performed in both 
endocardial and epicardial directions to account for potential errors in image 
fusion and the projection range is chosen to be large enough to extend into the 
LA myocardium but not so far as to project SI from other locations in the image. 
At ±3 mm, the projection should sufficiently account for all enhancement in the 
LA myocardium, which is approximately 1–4 mm thick. Signal intensities are 
then displayed as a number of standard deviations (SD) from the mean intensity 
of the atrial blood pool. 
An alternative method involves manually segmenting the epicardial and 
endocardial borders of the LA on each slice of the 3D LGE volume (Figure 2-3).80 
This defines the LA wall as the region of interest and the SI histogram for the 
entire LA wall can then be determined. Based on the histogram, an SI threshold 
is chosen to distinguish between enhanced and non-enhanced voxels. However, 
the selection of this cut-off value is to some extent arbitrary, will vary from 
patient to patient (depending on image quality and image contrast) and 
influences any further data interpretation or analysis. Setting a lower 
threshold/cut-off value will produce a processed image showing more 








Figure 2-3: An algorithm for the detection of LGE. The epicardial and 
endocardial borders of the LA are first segmented to extract the LA wall. The 
SI histogram of the LA wall is derived and a threshold is selected to 
distinguish between enhanced and non-enhanced voxels.80 
 
There are many potential sources of error in producing 3D representations of 
LGE of the LA (original image quality, image registration and selection of a 
threshold) and this has to be taken into account when making clinical 
inferences from the data, particularly those requiring high resolution 
information, such as small gaps in ablation lines.  
2.2.3.2 Pre-ablation imaging 
Irreversible remodelling of the LA is thought to limit the effectiveness of PV 
isolation for AF and to be an important factor impacting the success of the 
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procedure.88 Endomyocardial atrial biopsies in patients with lone AF show 
fibrosis in the LA wall.41 A non-invasive method of detecting the location and 
extent of these fibrotic areas before AF ablation might be able to predict the 
long-term success of the procedure in an individual patient. 
A landmark study assessed the role of LA LGE CMR in detecting the extent of 
atrial remodelling in 118 patients before AF ablation for either paroxysmal or 
persistent AF.80 Image quality was insufficient in 37 patients, leaving 81 
patients in the study. The authors identified varying degrees of LGE in the LA 
wall, with 43 patients having mild enhancement (<15% of the LA wall area), 30 
with moderate enhancement (15-35% of the LA wall area) and 8 with severe 
enhancement (>35% of the LA wall area). At six month follow-up, AF recurrence 
increased with pre-ablation enhancement, with 14% recurrence in the mild 
enhancement group, 43% in the moderate enhancement group and 75% in the 
severe enhancement group. The study concluded that LA LGE CMR is able to 
offer a non-invasive means of predicting disease severity and response to AF 
ablation.  
The same group later revised the extent of LA enhancement into a 4-stage 
classification system: Utah I (<5% enhancement), Utah II (5-20% 
enhancement), Utah III (21-35% enhancement) and Utah IV (>35% 
enhancement).83, 84 These studies once again suggested that the extent of pre-
existing LGE is proportional to the incidence of AF recurrence, despite there 
being comparable LGE across the four Utah stages on follow-up scans three 
months after ablation. There was no difference in this finding between patients 
with lone and those with non-lone AF. They further stated that a more extensive 
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ablation strategy was appropriate in those with more enhancement, and that in 
Utah IV ablation was unlikely to be successful.  
This non-invasive pre-ablation imaging has recently been extended to 
predicting the risk of stroke in AF. It is known that LA structural remodelling in 
AF increases the risk of thromboembolism89 and, therefore, the extent of LGE in 
the LA wall may be a predictor of stroke risk. Investigators used the Utah 
staging system to show that patients with more LA enhancement were more 
likely to have had a previous stroke and have a higher CHADS2 score90 than 
those with less LA enhancement.91 However, this has not yet been assessed 
prospectively.  
2.2.3.3 Post-ablation imaging 
The technique of LA LGE CMR after catheter ablation for AF was first described 
in 2007 in 23 patients in a study that attempted to quantify the extent of 
circumferential enhancement of the PVs on 2D reconstructions of the PV ostia.77 
However, unlike the studies in the previous section, this study did not show 
pre-ablation LGE in any patients. 
A similar technique was then used to assess the relationship between AF 
recurrence and the extent of post-ablation LGE at three months.78, 81 These 
studies, in cohorts of 46 and 86 patients, reported significantly less total LA wall 
enhancement in patients with AF recurrence. They also showed complete 
encirclement of only 39% of PVs at three months post-ablation, with the 
number of PVs encircled being proportional to procedural success. In the first of 
these studies, the authors did not report any significant pre-ablation 
enhancement, with only mild enhancement in four patients.78  
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The authors of these two studies suggested that certain patients may be more 
‘resistant’ to scar formation, although the mechanisms responsible are not 
understood. It may be that those with more pre-existing LA remodelling are less 
likely to form scar, although this would not be consistent with the finding of 
comparable LGE at three months across the four Utah stages.83  
Insights into the temporal formation of LA scar have also been revealed by LGE 
imaging.79 CMR scans at 24 hours post-ablation were repeated at three months 
in ten patients (and at six and nine months in 16 patients). This showed that 
LGE imaging within 24 hours of ablation overestimates the extent of 
enhancement at three months, suggesting a transient inflammatory response, 
which then resolves. This is due in part to LA wall oedema, shown on T2-
weighted (T2W) imaging, which has resolved by three months.51, 87 This thesis 
explores these LGE and T2W imaging findings in an animal model of acute and 
chronic atrial ablation injury. 
2.3 Atrial anatomy, volume and function  
The assessment of LA and PV anatomy by CMR can be used to help plan ablation 
procedures and monitor for their complications. These structures can be 
imaged using standard black-blood spin echo CMR techniques, which are 
sufficient to identify the LA and proximal PVs and their relationships to the 
surrounding structures. Further anatomical detail, particularly of the PVs, can 
be obtained using contrast-enhanced MR angiography, with protocols typically 
involving short TR, high flip angles and fractional echoes to provide highly T1-
weighted images with minimal flow artefacts.92-100 Spatial resolution is typically 
1-2 mm2 in plane with 2-4 mm slices, and a single 3D volume can be acquired in 
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a 10-20 second breath-hold. The sequence is not ECG-triggered, which can 
cause motion artefact of both the LA and PVs (the position of the PVs changes 
throughout the cardiac cycle97, 101). A gadolinium-based contrast agent is 
injected at 1-2 ml/s and a pre-contrast subtraction mask can be used, although 
this is not necessary since the background signal from the lungs is low. 
Acquisition timing is critical and this is achieved using a bolus timing scan102 
and multiple dynamics to ensure acquisition during peak contrast in the LA. 
An alternative anatomical protocol involves a non-contrast-enhanced 3D b-SSFP 
acquisition with a 2-3 mm isotropic resolution.87 This sequence uses the 
respiratory navigator to minimise motion artefacts and to ensure acquisition at 
end-expiration for all slices. The acquisition is ECG-triggered, with the length of 
the acquisition window set to maximum of 150 ms to minimise motion 
artefacts.  
Thereafter, either acquisition can be viewed on a workstation using multi-
planar reformatting to dynamically view 2D slices of the 3D dataset in any 
orientation (Figure 2-4). However, it is difficult to produce a single summary 
image of the anatomy; techniques employed include a MIP or 3D 
reconstructions to produce shaded or volume-rendered images (Figure 2-5).  
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Figure 2-4: Multiplanar reformat of a 3D b-SSFP acquisition. 
 
 
Figure 2-5: LA volume-render of a b-SSFP acquisition (top row) and MIP of 




2.3.1 Atrial volume and function 
Atrial enlargement is seen in a wide range of cardiac and pulmonary conditions 
and plays an important role in the development and maintenance of AF.103, 104 
Atrial size is a marker of LA structural remodelling, a predictor of AF and 
mortality, and a key determinant of therapeutic strategy in the management of 
AF.89  
Atrial volumes measured by cine CMR show a good correlation with volumes 
measured in cadaveric casts.105 The most accurate method of measuring atrial 
volume and function is the multiple slice method, whereby manual tracings of 
the atria are made on each cross-sectional image.106 However, this method is 
time-consuming and so simplified methods have been employed, using the 
single-plane area length method. This measurement is taken on a four-chamber 
acquisition, a technique previously used to determine LA and LV size using 
echocardiography107 and LV volume and function using CMR.108-110 However, 
one study found that the area length method underestimated LA volume and 
overestimated LA function compared with the multiple slice method.106 
CMR has been used to compare LA volumes in patients with paroxysmal AF 
with healthy controls, with one study showing significantly larger volumes in 
paroxysmal AF patients111 and another finding no significant difference.112 
Whilst CMR-measured LA volumes are significantly greater in patients with 
persistent AF than those with paroxysmal AF,113 there is no difference between 
patients with persistent and permanent AF, suggesting that LA dilatation 
stabilises once AF becomes persistent.114 
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CMR has also shown the immediate reduction in atrial systolic volumes 
following cardioversion.115 There was a further recovery of atrial dimensions at 
30 days and 180 days. However, only the RA volumes were completely 
normalised 180 days after cardioversion.  
Pre-ablation LA volume measured by CMR has been shown to be the main 
determinant of the outcome of PV isolation and linear ablation in a study of 240 
patients undergoing ablation for drug-refractory AF,116 whilst another CMR 
study suggested that, in a multivariate analysis, LA volume was not statistically 
significant in determining outcome from PV isolation for paroxysmal AF.117 CMR 
has also demonstrated a reduction in LA volume three to four months after PV 
isolation,118, 119 however there was no relationship between LA volume 
reduction and AF recurrence.118 
There are few data on the CMR assessment of LA function after AF ablation. In 
one of the aforementioned studies, there was a mild reduction in LA function 
following PV isolation.119 This finding is supported by another study of 33 
patients who underwent ablation for paroxysmal or persistent AF, in whom 
there was a mean reduction in LA ejection fraction of 14% following ablation.120 
However, another study, using velocity-encoded CMR, demonstrated an 
improvement in LA and LA appendage function six months following stepwise 
ablation for persistent AF.121 
2.3.2 Pulmonary venous anatomy and stenosis 
PV imaging is important for planning LA ablation procedures and for diagnosing 
PV stenosis following ablation. PV diameters are normally measured on the 
multi-planar reformat of the contrast-enhanced MR angiogram or the 3D b-SSFP 
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acquisition in a single plane at the ostia of the PV.92, 122-124 However, 
reproducibility is poor and identification of the true PV ostia can be difficult, 
because there is no well-defined border with the LA. Furthermore, the PV ostia 
are ovoid, not round, so measurements depend on the imaging plane.92, 93 
Measuring the PV diameter in the sagittal plane has been suggested to be the 
most reproducible method, which may be advantageous for serial 
examination.93 Additional measurement error can be introduced in non-cardiac-
gated angiography, because the PV diameter varies over the cardiac cycle with a 
maximum diameter during ventricular diastole.97, 125 
A 2D multi-slice breath-hold ECG-gated SSFP cine acquisition has been shown to 
have comparable precision with contrast-enhanced MR angiography.126 
However, both methods showed a significant range of intraobserver and 
interobserver agreement. No study has compared PV measurements using 
contrast-enhanced MR angiography and 3D b-SSFP acquisitions. 
Despite these potential inaccuracies in the measurements of PV diameters, CMR 
can provide an accurate assessment of the branching pattern of the PVs. In a 
study of 28 patients, variant PV anatomy was found in 38% of patients and 
patients with AF had larger PV diameters than matched controls.111 Another 
study, in a much larger cohort of 437 patients, found that only 40% of patients 
had a typical PV branching pattern of two left and two right PVs.113 A short and 
long common left trunk was found in 20% and 11% of patients respectively. A 
right middle PV was found in 30% of patients and two right middle PVs were 
found in 1.5% of patients. Atypical accessory PVs were documented in 6% of 
patients and 9% had a common left trunk with a right middle PV. 
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In the early years of AF ablation, RF ablation was delivered within the PVs and 
PV stenosis was not an infrequent complication.127 When severe, this 
complication can cause pulmonary hypertension and severe breathlessness. 
This complication led to a change in practice to deliver RF energy outside of the 
PVs, towards the PV antra. CMR can be used to diagnose PV stenosis, albeit with 
the caveats mentioned above, and several studies have used contrast-enhanced 
MR angiography in these circumstances.122, 128, 129 
2.3.3 Stroke risk 
Stroke is one of the most devastating complications of AF and thrombus 
formation within the LA appendage is thought to be the origin of most 
thromboemboli in AF.130 Whilst transoesophageal echocardiography (TOE) is 
the clinical standard for diagnosing LA appendage thrombus, TOE is invasive 
and has a small risk of serious complications. CMR is an alternative, non-
invasive technique for assessing the LA appendage. A study of 50 patients 
compared TOE with CMR and found that the LA appendage was easily 
visualised in all patients with CMR.131 Concordance between the detection of a 
high SI mass with CMR and thrombus with TOE was high. Another study of 97 
patients undergoing PV isolation showed 100% concordance between the two 
imaging modalities.132 However, in a study of 25 patients, contrast-enhanced 
CMR lacked diagnostic accuracy compared with TOE as the gold-standard.133 
CMR can also be used to predict stroke risk in patients with AF. 144 patients 
with non-valvular AF underwent CMR to assess LA appendage volume and 
dimensions.134 Patients with a history of stroke or transient ischaemic attack 
had higher LA appendage volumes and dimensions than those with no previous 
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history. Velocity-encoded CMR may be able to determine 3D flow patterns 
within the LA and LA appendage, providing insight into the mechanism of stasis 
and thrombus formation, however this remains a research tool.135 
 
The next chapter describes the physical principles of the CMR sequences 
described in this chapter. 
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3 Principles of cardiac magnetic resonance  
3.1 Introduction 
CMR is ideally suited to imaging the thin atrial wall – it is non-invasive, does not 
involve ionising radiation or have any known long-term harmful effects, has 
excellent spatial resolution and is able to distinguish between different tissue 
types based on their different physical properties.  
3.2 Nuclear spins in a magnetic field 
A hydrogen atom consists of a central nucleus that contains one proton, 
surrounded by a single electron. Nuclei have a quantum mechanic property 
called nuclear spin and a magnetic moment proportional to the nuclear spin.  
When an external magnetic field (the Bo field) is applied, the magnetic moments 
align in the direction of the external field (spin-up) or in the opposite direction 
(spin-down). In thermal equilibrium, more spins are in the spin-up state than in 
the spin-down state. The difference between the numbers of spins in each state 
is determined by a Boltzmann distribution and, at room temperature, this 
difference is in the order of a few parts per million.  
Once in an external magnetic field, the protons do not remain static. They 
precess akin to the cone shape formed by a spinning-top. The frequency at 
which they precess is known as the Larmor frequency (ω0) and is determined 
by the magnetic field strength (B0) and gyromagnetic ratio (γ), as described in 
the Larmor equation (ω0 = γ.B0). 
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The precession frequency is measured in (M)Hz, the gyromagnetic ratio in 
(M)Hz/Tesla and the field strength in Tesla. The gyromagnetic ratio is different 
for different materials/atoms – the value for hydrogen nuclei is 42.5MHz/Tesla. 
The z-axis is denoted as being parallel to the external magnetic field, whilst the 
x-axis and y-axis are perpendicular to the external magnetic field. As already 
described, more magnetic moments align in the direction of the magnetic field 
than in the opposite direction and so there is a net magnetisation in the z-axis 
once a subject is placed in the MR scanner. This is known as longitudinal 
magnetisation. 
3.3 Radiofrequency excitation 
CMR is performed by placing the patient within a strong and modifiable 
magnetic field. Once the subject is in the magnetic field, an RF pulse is applied to 
disturb the equilibrium state of the nuclear spins. This is only possible if the 
frequency of the RF band of the electromagnetic spectrum corresponds to the 
precession frequency of protons (they are in resonance), such that energy 
exchange from RF to the nuclear spins is possible. As the precession frequency 
of the protons is determined by the Larmor equation, this also dictates the 
frequency of RF required. The application of an RF pulse that is on resonance 
with the precessing hydrogen nucleus is termed excitation. 
When RF is applied, some spins go from the low to the high energy state. 
Furthermore, the RF pulse causes the spins to precess in step – it puts the 
protons in phase. This leads to a measurable transverse magnetisation. The 
angle between the z-axis and the new net magnetisation vector is known as the 
flip angle and its magnitude depends upon the amplitude and duration of the RF 
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pulse. Once the RF pulse is removed, the protons continue precessing at their 
precession frequency and this change in magnetic flux induces an electric 
voltage, which can be detected by an RF antenna – the MR signal. 
3.4 T1 and T2 relaxation 
After the RF field is switched off, the protons from the higher energy state 
return to the lower energy state. However, this is not an instantaneous process 
and not all protons do this at the same time. During this relaxation, energy is 
transferred from the protons to their surroundings, known as the lattice. 
Longitudinal relaxation is also, therefore, known as spin-lattice relaxation. A 
graph of longitudinal magnetisation against time is known as a T1 curve (Figure 
3-1) and the time constant of this process is the T1 time or longitudinal 
relaxation time. The T1 time is defined as the time to reach 63% of the 
equilibrium longitudinal magnetisation. 
Following removal of the RF pulse, the protons progressively become out of 
phase (they lose phase coherence). As a result, transverse magnetisation 
decreases and this is also known as spin-spin relaxation. A graph of transverse 
magnetisation against time is known as a T2 curve (Figure 3-1) and the time 
constant of this process is the T2 time or transverse relaxation time. The T2 
time is defined as the time at which transverse magnetisation has reduced to 
37% of its original value. 
The T1 and T2 values depend on the properties of the tissue and can therefore 
provide physical information. Water has a long T1 and long T2 value, whilst fat 
has a short T1 and short T2. T1 values are also strongly dependent upon the 
magnetic field strength. 
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Figure 3-1: The amount of magnetisation in the longitudinal plane 
gradually increases back to its original state and this is called T1 relaxation 
(left). At the same time the amount of magnetisation in the transverse plane 
gradually decreases, and this is called T2 relaxation (right).  
 
3.5 Pulse sequences 
Pulse sequences comprise a combination of RF pulses and/or gradient fields. 
The time from one RF excitation to the next is known as the repetition time, TR. 
3.5.1 Spin echo sequences 
Spin echo sequences begin with a 90 degree excitation pulse to flip the net 
magnetisation vector into the transverse plane. When the 90 degree pulse is 
removed, a free induction decay (FID) signal is produced. T2* dephasing also 
occurs, which describes the dephasing of transverse magnetisation caused by 
the combination of spin-spin interactions (T2 decay) and macroscopic magnetic 
field (B0) inhomogeneities. If a 180 degree pulse is applied at a time TE/2 (TE is 
the echo time) after the 90 degree pulse, the protons will start precessing in the 
opposite direction and the faster protons will begin to ‘catch-up’ with the 
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slower protons. At time TE, the protons will be temporarily almost back in 
phase, resulting in increased transverse magnetisation and, therefore, signal. 
This resulting signal is called a spin echo. The 180 degree pulse only 
compensates for the constant inhomogeneities of the external magnetic field, 
with no effect on temporally-varying inhomogeneities. Therefore, the obtained 
signal is T2 weighted. 
It is possible to keep repeating 180 degree pulses to give a series of spin echoes, 
however each one will have a lower intensity than the previous one (due to T2 
effects). A pulse sequence consisting of a 90 degree pulse followed by a 180 
degree pulse is known as a spin echo sequence.  
3.5.2 Gradient echo sequences 
The problem with spin echo sequences is that the acquisition time is relatively 
long because of the duration of RF and the long TR required. Gradient echo 
sequences are a faster imaging technique, which do not require a 180 degree 
pulse and use smaller flip angles (which require a shorter duration of RF) for 
data acquisition. Therefore, only part of the longitudinal magnetisation is 
converted into transverse magnetisation. A temporary additional magnetic field 
gradient is superimposed on the existing magnetic field to increase field 
inhomogeneities and dephase nuclear spins. The gradient is then applied in the 
opposite direction to rephase the spins and produce a gradient echo signal 
(Figure 3-2). Since the gradients can be applied rapidly, the minimum TE is 
much shorter than in spin echo sequences, and so the TR can also be reduced. 
However, gradient echo sequences are more susceptible to magnetic field 
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inhomogeneities than spin echo sequences. The obtained signal is dependent on 
T2*.  
With fast gradient echo imaging, the TR is usually shorter than T2* in most 
tissues. This means the transverse magnetisation may not have fully decayed 
before the next RF pulse occurs. The following RF pulses may then tip this 
residual magnetisation towards the longitudinal plane. If this process is not 
very well controlled the contribution of the transverse magnetisation can 
corrupt the image contrast. The easiest way to resolve this problem is to 
eliminate the transverse magnetisation before the subsequent RF pulse, a 
process called spoiled gradient echo. Another approach is known as balanced 
steady state free precession (b-SSFP), which has an improved signal to noise 
ratio (SNR) and contrast to noise ratio (CNR).  
3.5.2.1 Spoiled gradient echo 
A gradient echo sequence can be spoiled by either RF spoiling or spoiler 
gradients (or both). If RF spoiling is used, a phase is added to each successive 
RF pulse to avoid coherence. With spoiler gradients, an extra gradient is added 
at the end of the readout and slice selection gradient before the next RF pulse. 
This gradient causes dephasing of the residual transverse magnetisation. After a 
number of RF pulses and assuming that perfect spoiling is achieved, the 
transverse magnetisation is zero before each RF pulse and the magnetisation 
reaches a steady state.  
 62 
 
Figure 3-2: A gradient echo pulse sequence uses an RF excitation pulse that 
is variable. The magnetic moments within the transverse component of the 
magnetisation are dephased and are then rephased by a gradient pair.  
 
3.5.2.2 Balanced steady state free precession  
Balanced steady state free precession acquisitions are gradient echo sequences 
in which the net phase shift introduced by the gradients is exactly zero after 
each TR. In these sequences, the gradients are compensated by applying a 
gradient pulse with the opposite polarity at the end of each TR, which results in 
a net magnetisation vector that is not dephased. The images provided by b-SSFP 
sequences have an SI proportional to the T2/T1 ratio. Furthermore, due to the 
lack of net dephasing, the entire magnetisation vector contributes to the MR 
signal, giving higher SNR.  
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These characteristics have played an important role in cardiovascular imaging 
since the T2/T1 ratio is approximately four-fold higher for blood than 
myocardium. The b-SSFP sequence, therefore, provides a much higher contrast 
between blood and myocardium and an improved SNR compared to other 
gradient echo sequences. However, B0 inhomogeneities can cause additional 
dephasing and modification of the steady state signal. The resulting off 
resonance can result in dephasing of the magnetisation and collapse of the 
steady state signal, causing so-called banding artefacts. 
3.6 Cardiac MR sequences 
3.6.1 Inversion recovery sequences 
Inversion recovery (IR) sequences begin with a 180 degree pulse, which inverts 
the longitudinal magnetisation. After a given time, known as the inversion time 
(TI), data acquisition is carried out. Tissues with a shorter T1 value will have 
regained more longitudinal magnetisation by the time data is acquired and so 
the transverse magnetisation and obtained signal is dependent on tissue T1 
values. The contrast of the image depends primarily on the length of the TI. 
Inversion recovery can be used to produce heavily T1-weighted images as the 
180 degree inverting pulse achieves full saturation.  
3.6.1.1 Late gadolinium enhancement 
Late gadolinium enhancement (LGE) imaging uses a T1-dependent IR technique 
to exploit the significant shortening of T1 by gadolinium contrast agents, the SI 
being dependent upon the local tissue gadolinium concentration. Gadolinium is 
a small paramagnetic molecule and can enter the interstitial space in the 
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myocardium. In normal myocardium, the interstitial space is minimal, but is 
expanded in certain pathological states (e.g. fibrosis, inflammation, infarction 
and infiltration), so that sufficient gadolinium is present to be detected. 
Furthermore, gadolinium washes out of tissue capillary beds within minutes, 
but takes 10-30 minutes to wash out from the interstitial space. By imaging 
within this window using a TI where normal myocardium has a net 
magnetisation vector of zero (and therefore appears black or ‘nulled’), the 
difference with normal myocardium (from which gadolinium has washed out) 
can be exploited (Figure 3-3). 
  
Figure 3-3: If a TI is chosen at which normal myocardium has a net 
magnetisation vector of zero, gadolinium-containing tissues will have 
greater SI, maximising the contrast between the two tissue types. 
 
3.6.2 Contrast-enhanced magnetic resonance angiography  
Magnetic resonance angiography is a commonly used imaging technique for 
imaging cardiac and vascular anatomy. The relatively short scan time means 
that the acquisition can be performed within a single breath-hold, minimising 
respiratory motion artefacts. Using T1-weighted sequences, gadolinium 
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contrast agents improve the SNR by creating a high intravascular signal. Timing 
the MR acquisition with the arrival of contrast in the area of interest is crucial. 
There are many strategies to optimise the synchronisation of the acquisition 
and the arrival of the contrast bolus. Real-time low-resolution T1-weighted 
sequences can be used to track the arrival of contrast from the arm to the 
ascending aorta, and the scan is either automatically or manually triggered. 
Alternative methods include the use of a test bolus and automated bolus 
detection algorithms.  
 
Figure 3-4: Coronal, sagittal and transverse (axial) slices of a 3D MR 
angiogram, with the brightest SI in the LA. 
 
3.7 Encoding and image information 
To create an MR image, it is first necessary to localise the MR signal in three 
dimensions. The first step is slice selection, followed by locating (encoding) the 
signal along both axes of the image (frequency and phase encoding). These 
processes are performed by additional magnetic fields, which are superimposed 
on the external magnetic field, with location-varying strengths, known as 
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gradient fields. Therefore, different parts of the body experience different field 
strengths and so the precession/resonant frequency of protons is different, a 
process called spatial encoding.  
An RF pulse with a particular range of frequencies (bandwidth) can be applied 
to selectively excite a particular slice; the wider the range of frequencies, the 
thicker the slice. Alternatively, if the bandwidth is kept constant, the slice 
thickness can be altered by adjusting the slope of the gradient field along the 
slice encoding direction. Normally, in spin echo sequences, the slice selection 
gradient is switched on during application of the 90 degree excitation pulse and 
during the 180 degree refocusing pulse, to excite and rephase each slice 
selectively. In gradient echo sequences, the slice select gradient is switched on 
during the excitation pulse only. 
The frequency encoding gradient alters the field strength and, therefore, 
precession frequency along the axis of the gradient. The gradient, therefore, 
produces a frequency shift along its axis and the signal can be located along the 
axis of the gradient according to its frequency. The frequency encoding gradient 
is switched on when the signal is received and is often called the readout 
gradient. Equally, when the phase encoding gradient is switched on, the 
magnetic field strength, and therefore the precession frequency of protons 
along its axis, is altered. The phase encoding gradient is typically switched on 
between excitation and signal collection.  
The application of all gradients selects an individual slice and produces a 
frequency shift along one axis of the slice and a phase shift along the other. An 
individual signal within the image can now be located by their measured 
 67 
frequency and phase. The data points are acquired in an array known as k-
space. Usually k-space is filled linearly but it can also be filled with other 
patterns, for example radial. Data acquired in the central lines contribute the 
lower frequencies in the image (image contrast), while data acquired in the 
outer lines contribute higher frequencies (resolution). The scan time is the time 
to obtain all the required k-space information. Following data acquisition, k-
space is converted into an interpretable MR image by Fourier transformation. 
3.8 Image quality 
The choice of pulse sequence determines the weighting and quality of the 
images, and their sensitivity to different tissues/pathologies. Two of the main 
considerations for determining image quality are the SNR and CNR. 
The SNR is commonly determined as the ratio of the mean SI of a region of 
interest to the SD of the background signal. Many factors affect the signal 
strength such as the magnetic field strength, voxel volume, TR, TE and flip angle, 
receive bandwidth, coil type and contrast agents. CNR is defined as the 
difference in SNR between two adjacent areas and is therefore influenced by 
some of the same factors. 
3.9 Motion artefacts 
Cardiac and respiratory motion of the heart can strongly impair image quality. 
Several approaches have been presented to address this problem. 
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3.9.1 Cardiac motion 
Cardiac synchronisation 
Cardiac synchronisation is used to minimise motion artefacts arising from the 
beating heart and from pulsatile blood flow. The MR data acquisition is 
synchronised with the cardiac cycle using the ECG. The pulse sequence is 
triggered when the amplitude of the R-wave reaches its maximum voltage. 
Although the ECG signal obtained during MR scanning can be used for cardiac 
synchronisation, it suffers from artefacts due to magnetohydrodynamic effects 
and cannot, therefore, be used diagnostically. 
The ECG signal can be used in several ways to guide the acquisition. Prospective 
gating detects the R-wave and starts RF excitation and data acquisition after a 
certain delay time (known as the trigger delay). When using prospective cardiac 
gating, data acquisition must be completed before the start of the next cardiac 
cycle. If the acquisition overruns into the next cardiac cycle, the next R-wave is 
ignored, prolonging the scan.  
In retrospective cardiac gating, data are continuously acquired throughout the 
scan whilst monitoring the ECG signal. During reconstruction, time points are 
assigned to the acquired profiles with respect to the cardiac cycle. An 
interpolation process is then performed in order to reconstruct the desired 
number of cardiac phases. The advantage of this technique over prospective 
cardiac gating is that data for the entire cardiac cycle is obtained. 
 69 
3.9.2 Respiratory motion 
In order to avoid image degradation
 
from breathing artefacts, motion-compensation 
strategies are normally employed. These include breath-holding, the use of a 
respiratory belt and respiratory navigator echoes. 
Breath-holding 
Image artefacts caused by respiration can be reduced by breath-holding. 
However, for high-resolution imaging, and especially for 3D imaging, it is often 
not possible to acquire the data in a single breath hold. Patients may be unable 
to hold their breath repeatedly and changes in the breath-hold position can 
cause misregistration of the images in multi-slice acquisitions and artefacts in 
3D acquisitions.  
Respiratory belt 
The respiratory belt system is based on a pressure sensor fixed with a belt, 
which is placed around the waist of the patient. Due to the movement of the 
abdomen during a breathing cycle, the pressure on the sensor changes over 
time, which is used as a respiratory signal. The signal from the pneumatic belt 
sensor is normally used to gate the image acquisition to particular breathing 
phases.  
Respiratory navigator 
A one dimensional navigator is used in which the RF excitation pulse excites a 
slab or pencil beam of spins. The data is acquired along a single dimension 
(readout direction) and, by obtaining this information frequently, these 
projections can be used to determine diaphragmatic motion. With prospective 
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gating, image data are only acquired when the respiratory phase is within the 
predefined acceptance window (a window location near the end-expiratory 
phase is usually chosen). The acceptance window width (typically 3-6 mm) and 
window location are determined from navigator data acquired over a period 
before image acquisition starts. An acceptance window that is too wide will 
result in poor image quality, whilst a smaller acceptance window improves 
image quality, but results in longer scanning times as more data is rejected. 
 
Figure 3-5: A diagram showing the position of the respiratory navigator 
with respect to the diaphragm (left) and an idealised profile produced by 
the navigator, showing movement of the diaphragm (right). Red lines 
indicate the acceptance window. 
 
Whereas the physical principles and CMR sequences described in this and the 
previous chapter have principally been used for atrial imaging before and after 
ablation, the next chapter discusses how they can be applied to real-time MR-
EP. 
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4 Magnetic resonance-guided electrophysiology 
4.1 Introduction 
The use of CMR to guide EP procedures has several potential advantages over x-
ray fluoroscopy and conventional EAM systems. Perhaps the most significant 
potential advantage is the ability to image ablation lesion formation during the 
procedure, using a variety of imaging techniques. Furthermore, CMR allows 
rapid imaging in any plane, with the potential to visualise EP catheters in 
relation to real-time, high resolution cardiac anatomy. This avoids the errors of 
using pre-acquired CMR images with possible image registration errors. Finally, 
MR-EP eliminates patient and physician exposure to ionising radiation.  
A number of recent technical advances have allowed the development of 
comprehensive MR-EP systems, although translation into human studies 
remains limited. 
4.2 Intraprocedural ablation lesion imaging 
Traditional endpoints of EP procedures are conduction block across an ablated 
region or inability to induce a previously inducible arrhythmia. While these 
endpoints may be appropriate for simple arrhythmias including 
atrioventricular node- or atrioventricular reentrant tachycardia, they do not 
necessarily determine long-term procedural success for more complex 
substrate-dependent arrhythmias such as AF or ventricular tachycardia where 
electrical reconnection and arrhythmia recurrence are common.50, 136, 137 CMR 
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imaging techniques may be able to visualise areas of permanent damage, rather 
than relying on potentially transient electrophysiological endpoints. 
The first description of MR-EP was a study in 2000, in which continuous real-
time interactive CMR was used to position non-ferromagnetic catheters at the 
RV apex of six mongrel dogs.138 RF ablation was performed and ablated tissue 
imaged with T2W fast spin-echo and gadolinium contrast-enhanced T1-
weighted gradient-echo sequences. Lesion size by CMR was determined and 
compared with measurements at gross pathological examination. Ablated areas 
of myocardium appeared as hyperintense regions directly adjacent to the 
catheter tip and could be detected two minutes after RF delivery. Lesions 
reached maximum size approximately five minutes after ablation. Lesion size by 
CMR correlated well with postmortem lesion size (r=0.958). 
A subsequent study further investigated CMR imaging patterns following RF 
ablation.139 Using a power-controlled, cooled-tip ablation system, RF ablation 
lesions were created on the RV epicardium of ten mongrel dogs. T1- and T2W 
CMR images were acquired during a 12-hour follow-up period and compared 
with gross pathology. Lesions were successfully visualised with T1- and T2-
weighted images 30 minutes to 12 hours after RF ablation. T2 images were 
more consistent, displaying an elliptical, high-intensity core with a surrounding 
low-intensity rim, corresponding to zone of tissue necrosis and the transition 
zone, respectively. T1-weighted images had a lower contrast and there was no 
surrounding low-intensity rim. Lesion size and appearance were well defined 
and unchanged during the 12-hour follow-up. 
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Gadolinium-enhanced CMR has also been investigated for imaging ablation 
lesion formation. Using the same animal model as in the previous study, 
investigators performed T1-weighted fast gradient echo CMR following RF 
ablation and the injection of gadolinium contrast.140 In this study, four distinct 
phases of signal enhancement were observed. After gadolinium injection, RF 
lesions were initially seen as areas of low SI. Signal enhancement then 
progressed from the lesion periphery towards the lesion centre. Maximum 
enhancement was observed after one to two hours. During the ten-hour follow-
up period, contrast started to decrease but the lesions remained detectable. 
During the first three phases of enhancement (up to two hours after contrast), 
CMR lesion measurements correlated well with pathological findings. However, 
the time required for full renal clearance and the maximum allowable dose of 
gadolinium-containing contrast agents limit their use in serial lesion 
assessment during a procedure.141 Nevertheless, contrast-enhanced CMR may 
still be useful in evaluating gaps in ablation lesions at the end of a procedure. 
4.3 Increasing temporal resolution 
CMR can generate excellent spatial resolution by spreading data collection over 
multiple heartbeats. However, real-time CMR requires a careful balance of 
increased temporal resolution at the expense of spatial resolution. An in-plane 
resolution of 2x2 mm is needed for catheter visualisation and the target 
temporal resolution is 7 frames per second (fps), equivalent to conventional x-
ray fluoroscopy used in EP procedures. The first study of MR-EP used a 
temporal resolution of 1 fps, but the development of faster and stronger 
gradients permits increased frame rates. Improved gradient performance and 
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magnetic field homogeneity allows real-time imaging to be performed with b-
SSFP sequences, providing increased CNR compared with gradient echo 
sequences.142 Furthermore, parallel imaging techniques can improve temporal 
resolution without sacrificing spatial resolution.143, 144 
4.4 Catheter navigation and visualisation 
X-ray fluoroscopy images are 2D projection images, which lack depth 
information. This means that it is possible to see the entire catheter body and 
tip in a single image. However, 2D CMR depicts a slice through the body, such 
that curved catheters may pass in and out of the imaging plane. This can lead to 
misinterpretation of the catheter tip position, with consequent complications 
and inaccurate placement of ablation lesions. 
The catheter tip location can be visualised using interactive real-time sequences 
with manual adjustment of the imaging plane. However, for navigation within 
cardiac chambers, where the catheter tip is relatively mobile, this requires 
frequent image plane manipulation, which can reduce workflow efficiency. 
An alternative technique involves automatically directing the imaging plane to 
the catheter tip location using position sensors in the catheter. Three one-
dimensional projections along the x, y and z axes are taken sequentially and 
combined to identify the 3D position of the receiver coils in the catheter tip.145 
The tracking sequence can be interleaved with real-time imaging sequences so 
that the imaging plane is updated during device manipulation.144, 146 
Alternatively, the tracking position can be used to define the catheter tip in a 
multi-planar reformatted image or 3D surface reconstruction of a previously 
acquired 3D dataset. 
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4.5 Electroanatomical mapping 
CMR is able to produce detailed 3D images in any orientation and is, therefore, 
well-suited to navigating complex anatomy. However, this flexibility can also 
lead to potential operator disorientation or information overload, particularly if 
real-time imaging intersects the anatomy in an unfamiliar plane. Appropriate 
displays, user interfaces and 3D visualisations are, therefore, crucial to 
maximising workflow efficiency. 
4.6 Safety 
The most important consideration for translation of MR-EP from animal to 
human studies is demonstrating safety. The most straightforward safety aspect 
of MR-EP procedures (which applies to all procedures in an MR environment) is 
the avoidance of ferromagnetic materials. Defibrillation, not infrequently 
required during EP procedures, must be performed a safe distance from the 
scanner bore and monitoring systems, ablation and pacing sources and 
anaesthetic equipment must be placed outside the main static magnetic field. 
An additional safety concern of MR-EP procedures is significant heating due to 
RF-induced currents in long metallic objects (guide wires and metal braided 
catheters).147, 148 The simplest way to avoid this is to construct devices from 
non-metallic components. However, in structures requiring conductivity, 












Where methods are applicable to more than one of the following chapters, the 
details are given below to avoid repetition. However, the individual study 
protocols are retained within the individual chapters. 
5.1 Animal model 
All animal studies were undertaken at Aarhus University Hospital Skejby, 
approved by the Danish Animal Experiments Inspectorate and fully complied 
with Danish law on animal experiments (Dyreforsøgstilsynet approval number: 
2012/561-148).  
Female Danish Landrace pigs (approximately 40 kg) were used for all 
experiments without a recovery phase, whilst female Ellegaard Göttingen 
minipigs (approximately 30 kg) were used for all experiments with a recovery 
phase. Minipigs were used as, unlike the Danish Landrace pigs, they are already 
fully grown and so there is minimal weight change during the recovery period, 
which would invalidate pathological findings. 
5.1.1 General anaesthesia 
After an overnight fast the animals were pre-sedated with an intramuscular 
injection of azaperone (4 mg/kg) and midazolam (0.5 mg/kg). Intravenous 
cannulae (20 G) were placed in both ears and general anaesthesia was induced 
with intravenous ketamine (5 mg/kg) and midazolam (0.5 mg/kg). The animals 
were intubated and mechanically ventilated (Datex-Ohmeda ventilator, GE 
Healthcare; tidal volume 450 ml; respiratory rate 12/min). General anaesthesia 
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was maintained with a continuous intravenous infusion of propofol (3 
mg/kg/hr) and fentanyl (15 mcg/kg/hr). During anaesthesia, the animals were 
monitored using a continuous three-lead ECG, pulse oximetry (sited on the tail) 
and end-tidal CO2 measurements. Urinary catheters were placed for the 
duration of the experiments and the animals were kept hydrated with a 
continuous intravenous infusion of 0.9% normal saline (125 ml/hr). 
5.1.2 Femoral venous access 
Using a handheld Doppler probe (Huntleigh Healthcare, UK), the right femoral 
artery and vein were located. Using a Seldinger technique, two 8/9F sheaths 
were inserted into the right femoral vein, followed by an intravenous injection 
of 100 IU/kg heparin. 
5.1.3 Additional medication 
Where necessary, the heart rate was kept below 80 beats per minute using 
boluses of 5 mg of intravenous metoprolol. Episodes of AF lasting longer than 
five minutes were pharmacologically cardioverted with 50-100 mg of 
intravenous flecainide. 
5.1.4 Animal recovery 
For chronic experiments, minipigs were recovered from general anaesthesia 
and given a single dose of intravenous antibiotic (600 mg benzylpenicillin). 
Once fully conscious, the animals were returned to the farm, where they were 




At the end of the experiment, animals were euthanised with an intravenous 
bolus of phenobarbital (80 mg/kg). 
5.2 EP setup 
A clinical grade interventional EP setup was designed for these experiments 
(Figure 5-1), comprising CartoXPress (Biosense Webster, Diamond Bar, CA, 
USA) EAM system (COM Unit, Patient Interface Unit, computer workstation, 
repeater screen, location pad, location reference patch), x-ray fluoroscopy (GE 
Healthcare), pacing stimulator, RF generator (Stockert, Biosense Webster), RF 
indifferent electrode, 6F decapolar CS catheter and an 8F bidirectional ablation 
catheter (Thermocool SF, D curve, Biosense Webster, Diamond Bar, CA, USA). 
5.3 Macroscopic and microscopic examination 
The hearts were explanted and the RA was opened and photographed (Figure 
5-2). The hearts were then fixed in formaldehyde. Next, the ablation line and 
surrounding tissue were excised en bloc (Figure 5-3) and cut into 4 mm sections 
perpendicular to the ablation line (Figure 5-4). Each cross section was 
photographed and then dehydrated, embedded in paraffin, sectioned (3 μm 
sections) and stained with hematoxylin and eosin or Masson’s Trichrome for 




Figure 5-1: Interventional EP setup used for animal experiments.
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Figure 5-2: Explanted heart photographed immediately after explantation. 
The RA has been opened. SVC=superior vena cava; IVC=inferior vena cava; 
CS=coronary sinus. 
 
Figure 5-3: The same specimen as in Figure 5-2, after fixation in 
formaldehyde. The ablation line and surrounding tissue have been excised. 
SVC=superior vena cava; IVC=inferior vena cava; CS=coronary sinus. 
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Figure 5-4: Cross-sections (4 mm thick) through acute (left) and chronic 
(middle) ablation lines. An acute ablation lesion has been embedded in 
paraffin (right) in preparation for histological staining and examination. 
 
 
Figure 5-5: Paraffin-embedded 3 μm sections stained with haematoxylin 
and eosin (left) or Masson’s Trichrome (right). 
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5.4 Cardiac magnetic resonance 
All CMR acquisitions were performed on a 1.5 Tesla MR system (Achieva, 
Philips Medical Systems, Best, The Netherlands) and a five (for animal studies) 
or 32 (for human studies) element cardiac phased array coil. 
5.4.1 Planning 
First, survey and sensitivity encoding (SENSE) reference scans were obtained 
followed by a 2D multi-cardiac phase cine scan acquired in an approximate 
four-chamber orientation. From this scan, the trigger delay was determined for 
all subsequent scans. In order to minimise artefacts from atrial wall motion, the 
length of the acquisition window was set to maximum of 150 ms for all 
subsequent scans and the respiratory navigator was used to ensure acquisition 
at end-expiration for all slices.  
5.4.2 3D T2-weighted sequence 
Sagittal T2W images were acquired using a multi-slice Turbo Spin Echo (TSE) 
acquisition technique with a double IR pre-pulse to suppress the blood pool 
signal. Spectral pre-saturation with inversion recovery (SPIR) fat suppression 
was applied. The effective TE was set to 45 ms using linear profile ordering. The 
TR was twice the cardiac cycle length. The spatial resolution was 1.5x1.5 mm2, 
reconstructed to 1.0x1.0 mm, with a slice thickness of 3 mm. Approximately 20-
25 slices were acquired to provide complete coverage of the LA/RA. 
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5.4.3 3D balanced steady state free precession sequence 
Sagittal whole heart b-SSFP images were acquired with 2 mm isotropic 
resolution, reconstructed to 1.3 mm resolution, with a T2 preparation pulse (TE 
50 ms), a flip angle of 90 degrees and TE/TR of 4.3/2.2 ms. 
5.4.4 3D late gadolinium enhancement sequence 
Twenty minutes after the administration of 0.2 ml/kg Gadovist (Bayer 
HealthCare Pharmaceuticals, Berlin, Germany), 3D LGE imaging was performed 
with a respiratory-navigated, ECG-triggered IR turbo field echo (TFE) 
acquisition. The spatial resolution was 1.3x1.3x4 mm3, reconstructed to 
0.6x0.6x2 mm3, using TE/TR of 3.0/6.2 ms and a flip angle of 25 degrees. The TI 
was determined using a preceding Look-Locker sequence to achieve optimal 
suppression of ventricular myocardium. The scan was acquired in an axial 
orientation, typically with 30-40 slices to achieve complete coverage of the 
LA/RA.  
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6 Cardiac magnetic resonance and electroanatomical 
mapping of acute and chronic atrial ablation injury 
in the pig – a histological validation study 
6.1 Introduction 
Left atrial RF catheter ablation, of which PVI is the cornerstone, is a widely 
practised procedure for the treatment of AF.46 However, it is now apparent that 
acute achievement of PVI is seldom durable, and this has refocused the field on 
the mechanisms of RF injury in the LA. In turn, there has been a recent increase 
in the use of CMR to provide pre- and post-procedural non-invasive atrial tissue 
characterisation to assess patient suitability and response to catheter ablation51, 
77-80, 82-85, 87 and to guide both repeat catheter ablation82, 86 and real-time MR-EP 
procedures.150-153 
The use of CMR to characterise acute and chronic ventricular myocardial injury 
only became clinically accepted and in widespread use following 
comprehensive pathological validation,67 yet there has been no fundamental 
validation work on the CMR assessment of the atrium. This is of particular 
importance as controversy remains regarding the reproducibility and 
diagnostic ability of atrial CMR.154 Validation of atrial CMR would benefit from 
defining SI thresholds, which can distinguish between healthy and injured atrial 
tissue, rather than arbitrarily chosen SI thresholds used in clinical studies to 
date.51, 78, 80, 82-84, 87 
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Furthermore, invasive atrial endocardial voltage mapping, the current clinical 
gold standard for characterising the atrial substrate, has not been pathologically 
validated or systematically compared with CMR findings. Voltage thresholds in 
common clinical use have been extrapolated from ventricular studies 
comparing EAM with post-myocardial infarction scar155, 156 and not ablation-
induced injury. 
This chapter provides a comprehensive histopathological validation of CMR and 
endocardial voltage mapping of acute and chronic atrial ablation injury and 
explores the possibility of defining SI thresholds for T2W and LGE CMR 




Under general anaesthesia, as described in section 5.1.1 (page 77), eight female 
Danish Landrace pigs (mean weight 39 ± 1.8 kg) underwent pre-ablation CMR, 
followed by EAM and ablation according to the protocols described below. 
These animals were then immediately transferred for post-ablation CMR 
according to the same protocol, before they were euthanised. 
Eight Göttingen mini-pigs (mean weight 31 ± 2.9 kg) underwent the same 
protocol, but were recovered from general anaesthesia after post-ablation CMR 
and returned to the farm for eight weeks. After eight weeks these animals were 
anaesthetised again and underwent chronic CMR and EAM (without ablation), 
before they were euthanised.  
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6.2.2 Electroanatomical map and ablation 
Two 8F sheaths were placed percutaneously in the right femoral vein, followed 
by an intravenous injection of 100 IU/kg heparin. Fluoroscopy was used to 
position a 6F decapolar reference catheter in the CS. An 8F bidirectional 
ablation catheter (Thermocool SF, D curve, Biosense Webster, Diamond Bar, CA, 
USA) was advanced to the RA. A 3-dimensional (3D) geometry of the RA was 
created using CartoXPress (Biosense Webster, Diamond Bar, CA, USA) and a 
high-density pre-ablation peak-to-peak bipolar voltage map was constructed 
during proximal CS pacing. Linear RF ablation (25 W, 38oC, 8 ml/min irrigation) 
was performed from the SVC to the IVC along the posterior wall of the RA. 
Ablation was performed as a continuous drag with the catheter moved every 30 
seconds. The SVC to IVC line was chosen as the aim of this study was to create a 
reproducible transmural linear ablation lesion in all animals, so as to 
demonstrate signal intensity and voltage thresholds for complete, rather than 
incomplete, scar.  
Following completion of the intercaval linear lesion, a second high-density post-
ablation voltage map was immediately acquired during proximal CS pacing. 
Chronic voltage maps were created in the same way, but without ablation. 
Continuity of the intercaval lesion was confirmed by the presence of double 
potentials along the line, absence of pace capture (at 3 mA) and the presence of 
a new activation detour during CS pacing. However, as the aim of the study was 
to evaluate the relationship between ablation injury, voltage and CMR 
appearances, an absolute insistence on the presence of bidirectional conduction 
block was not made.  
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6.2.3 CMR 
Each CMR study included 3D T2W, 3D b-SSFP and 3D LGE imaging, as described 
in section 5.4 (page 83). 
6.2.4 Macroscopic and microscopic examination 
After the animals were euthanised, the hearts were explanted for macroscopic 
and microscopic examination as described in section 5.3 (page 79). 
6.2.5 Data analysis 
6.2.5.1 Electroanatomical maps 
Pre-ablation, post-ablation and chronic voltage maps were exported from 
CartoXPress and imported into software custom-written with Matlab. This 
allowed the voltage maps and data collection points to be reconstructed for off-
line analysis. Axial slices (perpendicular to the ablation line) were placed on the 
voltage maps at 4 mm intervals (the same as the macroscopic cross-sections) 
along the ablation line. For each slice, the centre of the ablation line was 
identified by minimising the weighted distance to the ablation points (Figure 
6-1). For the chronic voltage maps, which unavoidably had a different 
anatomical shell from the pre-/post-ablation maps, ‘ablation points’ were added 
manually to the estimated centre of the low voltage zone to represent the 
ablation line. A graph of endocardial voltage against distance from the centre of 





Figure 6-1: Top row – Pre-ablation, acute (immediately after ablation) and 
chronic (eight weeks after ablation) CartoXPress endocardial bipolar 
voltage maps in a posteroanterior view (all from the same animal). 
Voltages ≥1.0 mV are denoted in pink. Red circles indicate the site of linear 
RF ablation from the SVC to the IVC. Middle row - the same voltage maps 
have been imported in Matlab and reconstructed. Voltages ≥1.0 mV are 
denoted in blue. Green circles indicate the site of ablation. Grey circles 
indicate data sampling points. Axial slices (perpendicular to the ablation 
line) in white are shown at 4 mm intervals along the ablation line. For each 
slice, the centre of the ablation line was identified by minimising the 
weighted distance to the ablation points. For the chronic voltage maps, 
which unavoidably had a different anatomical shell from the pre-/post-
ablation maps, ‘ablation points’ were added manually to the estimated 
centre of the low voltage zone to represent the ablation line. Bottom row - 
graphs of endocardial voltage against distance from the centre of the 
ablation line (from -25 mm to +25 mm) for each axial slice. Red and blue 
lines indicate that values are ≤3 mm (non-interpolated) and ≥3 mm 
(interpolated) from a grey data sampling point respectively. Only non-




Pre-ablation, post-ablation and chronic T2W and LGE images were analysed 
using 3D medical image segmentation software (itk-SNAP Version 2.2.0). First, 
two blinded expert observers independently selected a reference region (LV 
myocardium for T2W and the atrial blood pool for LGE images) and the mean 
(and SD) SI for the reference region was calculated. Next, the two observers 
manually segmented the RA wall in the 3D volume by consensus (Figure 6-2A). 
Thresholds from 0 to 15 SD (at 0.1 intervals) above the reference SI were 
applied to the RA wall. A 3D segmentation was created for each threshold 
(where all pixels above the threshold SI were included in the segmentation) and 
the volume of the segmentation plotted against the SI threshold (Figure 6-2B). 
6.2.5.3 Macroscopic examination 
Using Image J image processing software (National Institutes of Health), two 
blinded expert observers manually segmented the total area of injury for each 4 
mm cross-section on the gross pathological digital photographs taken after 
fixation in formaldehyde, but before dehydration and staining for histological 
examination. For the acute specimens, the ablation lesion was defined as both 
the zone of pallor and the surrounding haemorrhagic border zone, whilst for the 
chronic specimens, the ablation lesion was defined as the zone of pallor alone 
(as there is no surrounding haemorrhagic border zone) (Figure 6-3).  The total 
volume of injury for each animal was calculated by summing the cross sectional 
areas and multiplying by the slice thickness. The mean value for the two 
observers was then taken. 
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6.2.6 Statistical analysis 
Variables are expressed throughout as mean ± SD, except for voltages, which 
are expressed as geometric mean and 95% confidence interval (CI). Student's t-
test for paired data was used to compare pre-ablation, post-ablation and 
chronic CMR segmentations. Student’s t-test for unpaired data was used to 
compare pre-ablation, post-ablation and chronic endocardial voltages. A 
significance level of p<0.05 was considered statistically significant. 
Interobserver variability for macroscopic pathological examination was 












Figure 6-2: A - Sagittal T2W (top row) and axial LGE (bottom row) CMR images. The red arrows indicate the reference region 
against which SI were compared (LV myocardium for T2W and the atrial blood pool for LGE images). The blue overlay indicates 
the region segmented as the RA wall (in this particular slice). These images are all pre-ablation, but the same technique was used 
for all image analyses. B - A graph for one post-ablation T2W image of segmentation volume (in cm3) against the SI threshold 
(expressed as the number of SD above the reference SI). Sample images are included to show the segmentation created (outlined 




Figure 6-3: Manually contoured acute (left) and chronic (right) ablation lesions.
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6.3 Results 
6.3.1 Electroanatomical maps 
All 16 animals survived until the end of the protocol and no animals were 
excluded from analysis due to premature death. Percutaneous femoral venous 
access could not be achieved in one animal and a femoral venous cutdown was 
required. Otherwise, there were no complications during any of the studies. 
There were a total of 16 pre-ablation, 16 post-ablation and eight chronic 
electroanatomical maps with an average of 545 ± 400 points per map. The 
average time to create a high-density map was 18.5 ± 9.5 minutes and the 
average duration of RF application was 11.6 ± 4.2 minutes. Whilst a new atrial 
activation pattern (Figure 6-4) and double potentials were seen in all 16 
animals immediately after ablation and also in the eight chronic animals, there 
was no change in the latest atrial activation time point (pre ablation 135 ± 30 
ms, post-ablation 142 ± 25 ms, chronic 131 ± 24 ms) (Table 1). 
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Animal Pre-ablation (ms) Post-ablation (ms) Chronic (ms) 
1 101 108  
2 133 124  
3 117 114  
4 135 122  
5 122 139  
6 177 163  
7 150 173  
8 130 169  
9 111 108 166 
10 129 136 137 
11 169 180 145 
12 200 169 95 
13 96 161 106 
14 133 120 122 
15 92 154 123 
16 165 133 150 
 
Table 1: Latest atrial activation time points (as measured from the CS 
pacing artefact) for all 16 animals. 
 
 
Figure 6-4: Isochronal local activation time maps before, immediately after 
and eight weeks following SVC-IVC ablation. The red line in the post-
ablation map indicates the site of the ablation line. 
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6.3.2 CMR 
There were a total of 16 pre-ablation, 16 post-ablation and eight chronic 3D 
T2W and LGE scans. Example images showing the site of ablation are shown in 
Figure 6-6. Qualitatively, no appreciable pre-ablation T2W or LGE enhancement 
was seen in any of the animals, but both T2W and LGE enhancement were seen 
in all animals post-ablation. Chronically, T2W enhancement had reduced, whilst 
LGE enhancement remained. 
The summary data and statistical significance values for the eight pigs are 
shown in Figure 6-7 A and B. For T2W and LGE images, segmented volumes 
were significantly greater for post-ablation images compared with pre-ablation 
images.  
The summary data and statistical significance values for the eight mini-pigs are 
shown in Figure 6-7 C and D. For T2W and LGE images, segmented volumes 
were significantly greater for post-ablation images compared with pre-ablation 
images. When compared with acute post-ablation images, there was a 
significant reduction in the segmented volume for chronic T2W images, but no 
statistical difference for chronic LGE images.  
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Figure 6-5: Average results for the 16 pre-ablation (left), 16 post-ablation (middle) and eight chronic (right) electroanatomical maps. 




Figure 6-6: Sagittal T2W (top row) and axial LGE (bottom row) CMR images pre-ablation (left column), acutely post-ablation 






Figure 6-7: Signal intensity thresholds from 0 to 15 SD above a reference SI were applied to the RA wall for T2W and LGE images 
and a 3D segmentation was created for each threshold. A and B show the results for the eight pigs, whilst C and D show the results 
for the eight mini-pigs. Values in the tables show the statistical comparison within each graph. Dashed lines indicate ±1 SD. 
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6.3.3 Macroscopic and microscopic examination 
Macroscopic photographs of acute and chronic ablation lesions, both 
immediately after heart explantation and after fixing in formaldehyde, are 
shown in Figure 6-9. Microscopic histology of acute ablation injury confirmed 
transmural injury with coagulative necrosis, haemorrhage and interstitial 
oedema, whilst chronic histology demonstrated transmural replacement of 
normal atrial wall with fibrous scar tissue (Figure 6-10). 
The mean acute volume of injury measured on the cross sections in the eight 
pigs was 2.75 ± 1.26 cm3, whilst the mean chronic volume of injury in the eight 
mini-pigs was 1.51 ± 0.53 cm3. However, when corrected for the difference in 
atrial area between the pigs and mini-pigs (7.48 ± 0.85 cm2 vs 4.39 ± 1.05 cm2), 
there was no significant difference (p=0.9) (Figure 6-8). The interobserver 
variability for acute and chronic measurements was 0.95 (95% CI 0.69-0.99) 




Figure 6-8: Mean lesion volumes for the acute and chronic animals. Error 
bar indicates 1 SD. 
 
6.3.3.1 Comparison with CMR segmented volumes 
When the CMR segmented volumes were compared with the macroscopic 
volumes of injury, the SI thresholds that best approximated macroscopic 
volumes were: 2.3 SD above the mean atrial blood pool SI for LGE post-ablation; 
3.3 SD above the mean atrial blood pool SI for LGE chronically; and 14.5 SD 
above the mean LV myocardium SI for T2W post-ablation (Figure 6-11). 
Chronically, T2W always underestimated the lesion volume, even at 0 SD above 
the reference SI. Thresholds were determined by the intersection with the line 
y=1 on Figure 6-11, which indicated the best match between average CMR 
segmented volumes and average macroscopic volumes. The individual 
thresholds for each animal are shown in Figure 6-12. 
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Figure 6-9: A and B - Macroscopic photographs from animals euthanised acutely after ablation. ‘A’ is immediately after heart 
explantation, whilst ‘B’ is after fixation in formaldehyde. C and D - Macroscopic photographs from an animal euthanised eight weeks 
after ablation. ‘C’ is immediately after heart explantation, whilst ‘D’ is after fixation in formaldehyde (the ablation lesion is outlined in 







Figure 6-10: A, B and C - Histology (stained with hematoxylin and eosin) of an acute ablation line at increasing levels of 
magnification demonstrating transmural injury with coagulative necrosis, haemorrhage and interstitial oedema. Scale bars in A, 
B and C are 1 mm, 500 µm and 100 µm respectively. Macroscopic cross-sections through a chronic ablation line (D - 4 mm section 
after fixation in formaldehyde; E - 3 μm section after staining with Masson’s Trichrome, with which fibrous collagen appears 
blue). F and G - Microscopic histology of a chronic ablation line stained with Masson’s Trichrome), demonstrating transmural 
replacement of normal atrial wall with fibrous scar tissue. Scale bars in F and G are 1 mm and 500 µm respectively.
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Figure 6-11: Graphs showing the comparison of CMR segmented volumes with macroscopic volumes of injury for T2W (left) and LGE 
(right). A value >1 on the y-axis suggests that CMR is overestimating the macroscopic volume, whilst a value of <1 suggests 
underestimation. Thresholds are determined by the intersection with the line y=1. Sample images are included to show the 
segmentation created (outlined in yellow) at these thresholds. Red and green dashed lines indicate ±1 SD. *=14.5 SD, †=2.3 SD, ‡=3.3 SD. 
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Figure 6-12: Signal intensity thresholds that best approximate macroscopic 
volumes for each individual animal. The average thresholds derived from 




This study was prospectively designed to provide objective T2W and LGE CMR 
SI and endocardial voltage thresholds for defining acute and chronic atrial 
ablation injury, by comparison with macroscopic and microscopic pathological 
examination. The principal findings can be summarised as follows: 1) LGE CMR 
SI thresholds of 2.3 SD (acutely) and 3.3 SD (chronically) above the mean SI of 
the atrial blood pool best approximate macroscopic volumes of injury; 2) T2W 
CMR overestimates the volume of ablation injury acutely, up to 14.5 SD above 
the mean SI of the LV myocardium, whilst T2W CMR underestimates the volume 
of ablation injury chronically regardless of the SI threshold used; 3) mean 
endocardial voltage at the centre of a CMR-confirmed linear atrial ablation 
lesion is 3.3 mV before ablation, 0.6 mV immediately after ablation and 0.3 mV 
chronically; 4) microscopic examination of a CMR-confirmed ablation line 
shows transmural coagulative necrosis acutely and transmural fibrosis 
chronically. 
6.4.1 CMR of ablation injury 
Several animal studies have shown that atrial and ventricular ablation lesions 
can be acutely visualised with CMR following thermal injury, but CMR 
visualisation of chronic ablation injury in an animal model has not previously 
been reported. T2W and contrast-enhanced T1-weighted CMR demonstrated a 
strong correlation between CMR lesion size and macroscopic examination 
following ablation at the right ventricular (RV) apex of six dogs.138 Another 
study described the gadolinium-enhanced T1-weighted appearances of acute RF 
ablation lesions created on the RV epicardium of eight dogs.140 Four distinct 
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phases of signal enhancement were observed over a follow up period of ten 
hours, which correlated well with pathological findings.  
However, visualising lesions in the thinner walled atria is inherently more 
challenging. Even at the current limits of CMR spatial resolution, the atrial wall 
is covered by only a few voxels and the contrast between acute injury or chronic 
scar/fibrosis and healthy atrium is less easily visualised than in the ventricle. 
Published studies investigating atrial CMR lesion measurements and 
pathological examination are limited and have been in the context of real-time 
MR-EP.150-152 One study showed a correlation between the size of four focal 
atrial ablation lesions, measured by T2W CMR and macroscopic examination, 
but only 30% of lesions could be visualised.151 Another demonstrated a 
correlation between the size of eight focal atrial and ventricular ablation lesions 
measured by T2W and LGE CMR and macroscopic examination, with a trend 
towards larger lesion size measured by T2W CMR.152 However, only the lesion 
diameter was measured in these studies - lesion volume was not taken into 
account. Most recently, investigators demonstrated the ability of CMR to 
visualise deliberate gaps in acute ablation lesions up to 1.4mm in size with a 
strong correlation between gap length identified using CMR and gross 
pathology.150 
Gadolinium-enhanced CMR has also demonstrated areas of atrial (and 
ventricular) non-enhancement within one hour of RF ablation,140, 157 which are 
most likely due to non-perfused necrotic atrial myocardium, analogous to the 
‘no-reflow’ phenomenon seen with CMR following acute myocardial 
infarction.64  Investigators have shown that these non-enhancing areas appear 
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to predict permanent LGE at three months following ablation, providing a 
potential early imaging marker of effective ablation injury.157 However, these 
non-enhancing regions progressively enhance as the time from gadolinium 
injection (and ablation) increases, with a marked difference between images 
acquired at 13 minutes and 27 minutes after injection. Investigators used an 
arbitrary SI threshold of more than three SD below the SI of normal LA wall to 
define non-enhancing regions. However, this would not be detected by the 
thresholding technique used in this study as the SI would be lower than the 
reference SI. In these animals, the volume of LGE acutely after ablation may, 
therefore, have been underestimated.  
6.4.2 CMR SI thresholds 
The aforementioned animal studies used arbitrary SI thresholds/image 
windowing to define areas of T2W and LGE enhancement, and changes in these 
values could make a significant difference to the lesion measurements. Whilst 
studies have suggested CMR SI thresholds to quantify myocardial scar in a 
range of conditions, including acute and chronic myocardial infarction and 
hypertrophic cardiomyopathy,74, 158 no studies have attempted to validate 
similar thresholds for acute or chronic atrial (or ventricular) ablation injury. As 
a result, a variety of SI thresholds to distinguish between healthy and injured 
atrial tissue have been used: two to four SD above the normal atrial wall SI to 
quantify LA pre-ablation fibrosis80 and three SD to quantify post-ablation 
injury.78, 82 In these and indeed any study, an alteration in the threshold would 
change the quantification.  
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6.4.3 Atrial endocardial voltage thresholds 
Endocardial voltage mapping before catheter ablation for atrial arrhythmias can 
help to characterise the underlying atrial substrate and identify areas of 
previous ablation injury.88 Most commonly, atrial scar is identified by a bipolar 
voltage of ≤0.05 mV – this threshold originates from the baseline noise in early 
EAM systems25 and has been propagated through the literature and clinical 
practice without published pathological validation. Equally, thresholds to 
identify “low voltage”, but not scarred, atrial tissue have generally been 
extrapolated from ventricular studies of post-myocardial infarction scar. In 
animal models, bipolar voltages of ≤1.0 mV and ≤0.5 mV best correlated with 
pathological infarct size.155, 156 In a human study of ischaemic and non-
ischaemic cardiomyopathy, authors defined abnormal endocardium as a bipolar 
electrogram of <1.5 mV and “densely scarred” endocardium as <0.5 mV.159 
In this study, the mean bipolar voltage at the centre of the ablation line was 0.6 
mV acutely and 0.3 mV chronically. These values would suggest that using a 
threshold of ≤0.05 mV to define atrial scar could significantly underestimate the 
extent of previous ablation injury, perhaps leading to inaccurate interpretation 
of voltage data and even unnecessary ablation during a redo atrial ablation 
procedure.  
There was a statistically significant reduction in voltage (compared with pre-
ablation voltages) almost 2 cm either side of the centre of the line. There are 
several potential reasons why the area of recorded low voltage may be greater 
than the actual size of the ablation line: 1) at any point, the measured bipolar 
voltage depends on the tissue in the surrounding area, even if outside of the 
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zone of histological damage; 2) when creating an intercaval ablation line in the 
porcine RA, the catheter sits in a concave groove, such that the contact area may 
be larger than if perpendicularly opposed to a flat piece of tissue; 3) catheter, 
cardiac and respiratory motion may cause inaccuracies in the electroanatomical 
shell. 
6.4.4 Pathology of acute and chronic atrial ablation injury 
The pathology of acute RF atrial ablation injury in animal models is well 
established and is characterised by coagulation necrosis,160 as seen in this 
study. However, the microscopic features of chronic atrial ablation injury are 
much less well described due to the increased complexity in performing 
recovery animal experiments. Transmural myocardial fibrosis with areas of 
chronic inflammatory cell infiltration was seen in pigs four weeks after linear 
non-irrigated ablation in the RA.161 In open-chest beating heart sheep and dog 
models of RF ablation, there was replacement of the atrial myocardium with a 
fibrin and collagen matrix 30 days after ablation.162, 163 In the present study, 
animals were recovered for eight weeks to ensure a representative model of 
chronic ablation injury and histological findings were in keeping with the 
aforementioned studies, with transmural fibrous scar. Whilst CMR findings 
were compared with macroscopic volumes of injury, the microscopic histology 
in this study provided confirmation of transmural acute and chronic atrial 
ablation lesions. 
6.4.5 Limitations 
1) Extrapolation of results to humans is always a potential limitation of animal 
models. The LA is the predominant target of catheter ablation for AF and so 
 115 
clinical CMR studies have focused on LA ablation. The porcine LA does not 
closely resemble the human LA and its structure is not conducive to the 
reproducible deployment of a linear ablation lesion. For this reason, ablation 
was performed on the thin posterior RA wall, which is more comparable to the 
human LA. 
2) The CMR thresholds identified in this study are for the identification of post-
ablation injury and are not applicable to quantification of de novo atrial fibrosis, 
for which a specific animal model would be required. 
3) Determining volumes of injury on CMR images and pathological examination 
are challenging, particularly in the thin-walled atrium. Both require a subjective 
judgement (to segment the RA wall on CMR and to segment the ablation lesion 
on pathology), which was reduced as far as possible by the use of two blinded 
expert observers for each measurement. Furthermore, shrinkage of the 
pathological specimens may also occur during the preserving process. 
4) Surface coil proximity, sequence parameters, body mass index, haematocrit, 
renal function and field strength can all affect T2W and LGE SI. Furthermore, 
there is currently no consensus on the optimum timing of atrial LGE CMR after 
contrast administration, or on the choice and dose of contrast agent, which can 
also affect SI. In this study, these parameters were chosen based on previously 
published studies of atrial CMR and clinical experience. The clinical applicability 
of the SI thresholds derived in this study would have to take these 
considerations into account and these variables may explain the variation of the 
SI thresholds between animals.  
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6.5 Conclusions 
This study presents the first histopathological and electroanatomical validation 
of CMR to define acute and chronic atrial ablation injury, including SI thresholds 
that best match histological lesion volumes. However, the wide range of 
individual SI thresholds across the animals suggests that these values should be 
applied cautiously and that larger numbers would be needed to define these 
more accurately. Whilst continuous infusions of gadolinium (to achieve contrast 
equilibrium) have been shown to quantify diffuse ventricular myocardial 
fibrosis,164 this technique would not be suitable for atrial LGE quantification due 
to the high blood pool signal. In the future, further validation of SI thresholds of 
atrial injury is likely to require the development of high-resolution non-contrast 
enhanced T1 mapping techniques. 
The endocardial voltage thresholds defined in this study challenge currently 
used clinical values and application of these thresholds may allow a more 
accurate assessment of the underlying atrial substrate immediately after 
ablation and before repeat catheter ablation for atrial arrhythmias, potentially 
preventing unnecessary ablation. 
 
In the next chapter, the SI and voltage thresholds defined in this chapter are 
applied to a cohort of patients who underwent CMR prior to repeat catheter 
ablation for AF or AT. 
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7 Atrial arrhythmias following catheter ablation – 
cardiac magnetic resonance prediction of 
endocardial voltage and gaps in ablation lesion sets 
7.1 Introduction 
In appropriately selected patients with paroxysmal and persistent AF, catheter 
ablation is an effective treatment with freedom from AF reported in 56-89% of 
cases at one year.18 However, following ablation, a significant proportion of 
patients re-present with either AF or AT, often necessitating repeat procedures. 
Pulmonary vein reconnection is common and conduction across previously 
complete linear and circular ablation lesions is frequently seen at repeat 
catheter ablation procedures,136, 137 providing a possible explanation for the 
modest success rates.  
LGE CMR has been used to assess patient suitability and response to catheter 
ablation51, 77-80, 82-85, 87 and to guide repeat catheter ablation.82, 86, 165, 166 Previous 
studies in a relatively small number (n=11-13) of patients undergoing repeat 
catheter ablation have suggested a qualitative82 and quantitative165, 166 
relationship between areas of LGE and areas of low endocardial voltage. 
However, there is controversy regarding the reproducibility and diagnostic 
ability of atrial LGE CMR to reliably identify ablation lesions and their 
distribution.167 Furthermore, while one study demonstrated that LGE CMR can 
predict electrical reconnection by identifying gaps in ablation lesions,82 another 
has shown the opposite.165 
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Given these conflicting findings, this chapter investigates atrial LGE CMR to 
determine its relationship with atrial bipolar voltage recording, and also to 
investigate its potential as a predictor of electrical reconnection in patients 
undergoing repeat catheter ablation. 
7.2 Methods 
7.2.1 Patients 
Twenty patients requiring a clinically indicated repeat LA catheter ablation 
were studied. All had previously undergone LA catheter ablation for paroxysmal 
AF, persistent AF or AT. The index procedure for patients with paroxysmal AF 
was a PV wide area encirclement alone. For patients with persistent AF, the 
index procedure was a stepwise ablation approach incorporating wide area PV 
encirclement, electrogram-guided ablation and linear lesions at the LA roof, 
mitral isthmus and CTI as deemed appropriate. Patients presenting in AF on the 
day of the repeat procedure or with any contraindication to CMR were excluded 
from the study. 
7.2.2 CMR 
CMR was performed 2-3 weeks prior to repeat catheter ablation and included 
3D b-SSFP and 3D LGE imaging, as described in section 5.4 (page 83). Example 
LGE images are shown in Figure 7-1. 
7.2.3 Ablation procedure 
Class I and III antiarrhythmic medications, with the exception of amiodarone, 
were discontinued at least five half-lives prior to the procedure. Patients taking 
warfarin discontinued this five days before the procedure and were 
 119 
administered with subcutaneous low molecular weight heparin for three days 
before ablation. In two patients, the procedure was performed on uninterrupted 
warfarin.168 In patients with an original diagnosis of persistent AF or a 
CHADS2Vasc score 2, transoesophageal echocardiography was performed 
prior to the procedure to exclude intracardiac thrombus. 
At the start of the ablation procedure, a 6F decapolar catheter was placed in the 
CS to provide a reference for EAM. For procedures performed under general 
anaesthesia, TOE was used to guide transseptal puncture. For those performed 
under conscious sedation, fluoroscopy alone was used to guide a single 
transseptal puncture through which two SRO sheaths were passed to the LA. 
Immediately after needle access to the LA, intravenous heparin was 
administered to achieve an activated clotting time ≥300 seconds. The SRO 
sheaths were used to place a 3.5 mm tip irrigated ablation catheter 
(Thermocool, Biosense Webster) and a 20-pole circumferential mapping 
catheter (Lasso, Biosense Webster) in the LA. 
A 3D geometry of the LA was created using the Carto 3 EAM system (Biosense 
Webster). A high-density pre-ablation peak-to-peak bipolar voltage map was 
constructed using points acquired with the ablation catheter in order to give 
coverage of the entire LA. Tissue contact was determined by electrogram 
amplitude and distance from the endocardial shell. The catheter was held in 
each position for 5-10 seconds. The voltage map was constructed in either sinus 
rhythm or AT, according to the presenting arrhythmia. 
The circumferential mapping catheter was positioned sequentially in the PVs to 
assess for PV-LA reconnection. In sinus rhythm, conduction across the LA roof 
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and left lower PV-mitral isthmus line (‘mitral line’) was also assessed using 
previously validated pacing techniques.169, 170  
For patients with an original diagnosis of paroxysmal AF and in sinus rhythm, 
the procedural endpoint was re-isolation of the PVs, achieved by targeting the 
site(s) of PV reconnection(s) and verification of conduction block at the sites of 
any previous linear lesion. For patients presenting in AT, the procedural 
endpoint was termination of tachycardia, re-isolation of incompletely isolated 
PVs and achievement of conduction block across linear lesions. 
7.2.4 CMR image processing 
CMR images were not analysed before repeat ablation and the procedure was 
performed without any of the CMR anatomical or LGE information available to 
the operator.  
CMR images were processed according to previously described methods.51, 87 
Following creation of the 3D volumes, the first step was to perform an 
automatic segmentation of the LA using model-based segmentation (Philips 
segmentation plug-in for Graphical Interface for Medical Image Analysis and 
Simulation (GIMIAS), Universitat Pompeu Fabra, Barcelona). This technique 
aims to fit a standardised cardiac model (created as an average from a patient 
library) to the b-SSFP acquisition using contrast boundaries. The LA 
segmentation was extracted, but invariably required slice-by-slice manual 






Figure 7-1: Transverse slices from 3D LA LGE CMR scans from five different patients
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The second step involved image registration between the LGE and b-SSFP 
acquisition, using the information stored in the DICOM headers and the Image 
Registration Toolkit (Department of Computing, Imperial College). As the b-
SSFP and LGE acquisitions have different resolutions (both in-plane and in the 
slice direction), the LGE acquisition is interpolated during this registration 
process to fit the resolution of the b-SSFP acquisition. 
The final step was the projection of the image-registered LGE acquisition on to 
the segmented LA shell. Vectors at a normal to each vertex on the LA shell (a 
triangular mesh) were projected and the maximum SI within 3 mm of the 
surface was selected as the intensity for that vertex (a MIP). Signal intensities 
were then displayed on the 3D LA shell as a number of SD from the mean SI of 
the atrial blood pool to avoid the need for thresholding (Figure 7-2). 
7.2.5 Comparison of CMR signal intensity and endocardial voltage 
Voltage maps were exported from Carto 3 and imported into software custom-
written with Matlab (The Mathworks, Matick, USA), so that the voltage maps 
and data collection points could be reconstructed for off-line analysis. The CMR-
segmented LA shells were registered to the Carto 3 LA shells using a two-step 
process: 1) landmark registration (using the PVs and LA appendage as 
landmarks) and 2) iterative closest point registration. This allowed the LGE 
CMR SI to be projected on to the Carto 3 LA anatomy using point 
correspondence between the two LA shells (Figure 7-3). Thereafter, for each 
Carto 3 sampling point, the bipolar endocardial voltage and LGE CMR SI were 
extracted to allow a point-by-point comparison. 
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Figure 7-2: Top row - 3D LA LGE CMR reconstruction showing an SI ‘gap’ at 
the inferior right lower PV-LA junction (arrow). Bottom left - 3D 
reconstruction of a patient with previous PV isolation for paroxysmal AF. 
Bottom right - 3D reconstruction of a patient with previous roof line 
ablation. The scale bar applies to all three reconstructions and SI are 
expressed as the number of SD from the mean SI of the atrial blood pool. 
 
7.2.6 CMR analysis of gaps in ablation lesions 
The presence or absence of gaps in ablation lesions on 3D CMR reconstructions 
depends on the SI threshold chosen to denote ‘scar’. A lower threshold will 
result in more ‘scar’, whereas a higher threshold will result in more ‘gaps’. In 
order to avoid selecting an arbitrary threshold, it was necessary to develop an 
objective user-independent method for detecting gaps.  
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Figure 7-3: Top row - Carto LA anatomical shell (left) and bipolar 
endocardial voltage map (right). Middle row: CMR LA anatomical shell (left) 
and LGE SI map. Bottom row - Fusion of the Carto and CMR LA anatomical 
shells by landmark and iterative closest point registration (left) and LGE SI 
map projected on to the fused Carto shell (right). 
 
Using custom-written software, a path was traced around the left and right PV 
antra, the LA roof line and the mitral line on the CMR-segmented LA shell 
(without registration to the Carto 3 shell). For each vertex along these paths, the 
mean SI within 10 mm was extracted. The minimum intensity (LGEmin) recorded 
on these paths represents the ‘weakest link in the chain’ and the most likely site 
for reconnection, on the basis of LGE information (Figure 7-4). The mean SI 
(LGEmean) of the path gives an assessment of the total scar burden along the 
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path. The values of LGEmin and LGEmean were compared with the electrical 
integrity of the lesion sets (assessed at the time of repeat catheter ablation).  
 
Figure 7-4: A path was traced around the left and right PV antra, the LA roof 
line and the mitral line on the CMR-segmented LA shell (the right PV antra is 
shown for example purposes). For each point along these paths, the mean SI 
within 10 mm was extracted. The minimum intensity (LGEmin) recorded on 
these paths represents the ‘weakest link in the chain’ and the most likely site 
for reconnection, on the basis of LGE information.  
 
7.2.7 Statistical analysis 
Continuous variables are expressed throughout as mean ± SD, except where 
stated otherwise, and were compared using Student's t-test for unpaired data. 
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One-way ANOVA with a post test for a linear trend was used for multiple 




Twenty patients (17 male, 3 female; mean age 59 ± 7 years) completed the 
study. Patient characteristics are shown in Table 2. The median number of 
previous ablation procedures was 2 (range 1-5). The original diagnosis was 
paroxysmal AF in 11 patients, persistent AF in eight patients and AT in one 
patient. The arrhythmia at the time of the redo procedure was paroxysmal AF in 
ten patients and AT in ten patients.  
7.3.2 Comparison of CMR signal intensity and endocardial voltage 
There were a total of 6767 voltage measurements in the twenty patients (mean 
number of points per patient was 342 ± 214). 119 (1.8%) of the points were 
≤0.05 mV (the current clinical thresholds to define atrial scar), whilst 1819 
(27%) of the points were ≤0.3 mV (the threshold defined in the previous 
chapter). To demonstrate a qualitative comparison between the two datasets, 
voltage maps thresholded to these two values are shown in Figure 7-5, 














Figure 7-5: For all 20 patients, endocardial voltage maps are shown without 
thresholding and at two different thresholds (where blue indicates values 
greater than the threshold and red/green indicates values less than the 




For each of the voltage points, the corresponding CMR SI was extracted as 
described to allow point-by-point comparison of bipolar voltage and CMR SI. 
Examples of co-registered voltage maps and CMR SI maps are shown in Figure 
7-3. The summary data are shown in Figure 7-6. There is a very weak 
correlation between the two measurements (R2=0.018) with low voltage 
occurring across a large range of SI.   
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Original diagnosis (n) 
 Paroxysmal AF 






Recurrent arrhythmia (n) 





Coronary artery disease (n) 0 (0%) 
Smoking (n) 1 (5%) 
Valve disease (n) 1 (5%) 
Hypertension (n) 2 (10%) 
Diabetes mellitus (n) 2 (10%) 
CVA/TIA (n) 2 (10%) 
LVEF (%) 53 ± 3 























AT=atrial tachycardia; CVA=cerebrovascular accident; 
TIA=transient ischemic attack; LVEF=left ventricular 
ejection fraction; LA=left atrial 
 




Figure 7-6: Scatter plot to show the endocardial voltage and LGE CMR SI 
(expressed as the number of SD above the mean SI of the atrial blood pool) 
for all 6767 data points. R2=0.018. 
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Previous studies have transformed these data by splitting the CMR SI into 
bins166 or by simply dividing the CMR data into either ‘normal’ or ‘scar’.165  
The former approach is shown in Figure 7-7, demonstrating a statistically 
significant negative trend in mean bipolar (p<0.0001) voltage as CMR signal 
intensity increases. Receiver operating characteristic (ROC) analyses to 
determine voltage thresholds to separate contiguous pairs are shown in Figure 
7-8.  
The latter approach is shown in Figure 7-9, using the chronic LGE threshold of 
3.3 SD derived in the previous chapter to distinguish between ‘normal’ and 
‘scar’. This demonstrates that SI below 3.3 SD are associated with a significantly 
higher voltage than SI above 3.3 SD (1.27 ± 1.3 mV vs 0.94 ± 1.1 mV, p<0.0001). 
A ROC analysis to determine the voltage threshold to separate the two 
populations is shown in Figure 7-10. The percentage of the total LA surface area 
with SI greater than this threshold was the same for patients with paroxysmal 
AF and AT recurrences (17.9 ± 11% vs 17.4 ± 11%; p=0.92) 
The results of performing the analysis the other way round, to assess the ability 
of a voltage threshold (0.3 mV as defined in the previous chapter) to determine 
LGE SI are shown in Figure 7-11. A ROC analysis to determine the LGE SI 




Figure 7-7: The data from Figure 7-6 have been transformed by splitting the 
LGE CMR SI into bins and is presented as a dot-plot of endocardial voltage 
against LGE CMR SI (expressed as the number of SD above the mean SI of the 
atrial blood pool) for all 6767 data points. Error bars indicate mean ± SD.  
 136 
 
Figure 7-8: Receiver operating characteristic (ROC) analyses to show the 
predictive ability of different SI pairs to determine endocardial voltage. 
AUC=area under curve. 
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Figure 7-9: The data from Figure 7-6 have been transformed by splitting the 
LGE CMR SI (expressed as the number of SD above the mean SI of the atrial 
blood pool) into two categories (<3.3 SD ‘normal’ and >3.3 SD ‘scar’). 





Figure 7-10: Receiver operating characteristic (ROC) analysis to show the 
predictive ability of an SI threshold of 3.3 SD to determine endocardial 




Figure 7-11: The data from Figure 7-6 have been transformed by splitting 
the endocardial voltage into two categories (<0.3 mV ‘scar’ and >0.3 
‘normal’). LGE CMR SI (expressed as the number of SD above the mean SI of 






Figure 7-12: Receiver operating characteristic (ROC) analysis to show the 
predictive ability of a voltage threshold of 0.3 mV to determine LGE SI. 
AUC=area under curve. 
 
7.3.3 CMR analysis of gaps in ablation lesions 
All patients had previously undergone PVI. There was right upper PV 
reconnection in eight patients, right lower PV reconnection in 12 patients, left 
upper PV reconnection in ten patients and left lower PV reconnection in ten 
patients. When assessed as pairs, there was right PV reconnection in 13 patients 
and left PV reconnection in 12 patients. Six patients had previously undergone 
LA roof line ablation, but only four of these remained blocked. Five patients had 
previously undergone mitral line ablation, but only three of these remained 
blocked. 
The values for LGEmin and LGEmean for reconnected/unblocked and 
isolated/blocked lesions are summarized in Table 3. There were no statistically 
AUC=0.57 
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significant differences. The data for individual patients are shown in Figure 
7-13, Figure 7-14, Figure 7-15 and Figure 7-16. 
 
 LGEmin p value LGEmean p value 
 
Right PVs 
Reconnected 0.79 ± 1.11  
0.13 
3.25 ± 1.88  
0.19 
Isolated 0.11 ± 0.15 2.20 ± 1.07 
 
Left PVs 
Reconnected 0.23 ± 0.41  
0.67 
1.83 ± 0.75  
0.43 
Isolated 0.15 ± 0.25 2.19 ± 1.22 
 
Roof line 
Unblocked 1.20 ± 2.05  
0.73 
2.44 ± 2.73  
0.60 
Blocked 0.74 ± 1.38 1.68 ± 1.25 
 
Mitral line 
Unblocked 1.26 ± 2.00  
0.42 
2.44 ± 1.67  
0.13 
Blocked 1.50 ± 0.52 4.02 ± 0.22 
 
Table 3: Summary LGEmin and LGEmean values for reconnected/unblocked 







Figure 7-13: Individual LGEmin values for reconnected (⦁) and isolated veins 










Figure 7-14: Individual LGEmin values for unblocked (⦁) and blocked ablation 









Figure 7-15: Individual LGEmean values for reconnected (⦁) and isolated veins 






Figure 7-16: Individual LGEmean values for unblocked (⦁) and blocked 




This study was designed: 1) to investigate the relationship between LGE CMR SI 
and LA endocardial voltage in patients undergoing repeat catheter ablation for 
LA arrhythmias; 2) to define an objective user-independent method for 
assessing the ability of LGE CMR to predict electrical isolation or reconnection 
of LA ablation lesions.  
The principal findings can be summarised as follows: 1) whilst it is possible to 
demonstrate a negative correlation between mean endocardial voltage and CMR 
SI, the raw data shows that the point-by-point relationship is weak; 2) low 
endocardial voltage can occur at sites of low and high CMR SI, suggesting that 
CMR SI thresholds are poor predictors of endocardial voltage; 3) low CMR SI 
(LGEmin) occur at the site of both electrically isolated and connected ablation 
lesions, indicating that there is no clinically useful threshold to determine 
electrical integrity of LA ablation lesions. 
7.4.1 Correlation between LGE CMR and LA endocardial voltage 
In a retrospective analysis of 24 patients presenting to a single centre for repeat 
catheter ablation of AF, 13 patients had voltage maps with >100 points and 
interpretable LGE CMR scans.82 The authors demonstrated a qualitative 
correlation between regions of LGE and low voltage in all patients and a 
quantitative relationship (R2=0.57) by subdividing the LA into 18 regions and 
scoring the extent of LGE and low voltage on a scale from 0-3.  
A study of ten patients, by different authors, demonstrated initial experience 
with co-registration of LGE CMR SI with endocardial voltage mapping.165 In this 
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study, authors used manual segmentation to distinguish between areas of visual 
non-enhancement and enhancement in the LA wall to create a binary (‘scar’ vs 
‘normal’) 3D LGE CMR reconstruction. They then determined whether each 
voltage point (mean number of points 90 ± 24, total of 893 points) fell within an 
area of co-registered ‘scar’ or not. They demonstrated that the mean voltage 
within areas of CMR ‘scar’ was lower than the mean voltage within ‘normal’ 
areas on CMR. However, whilst the mean voltages were statistically different, 
there was almost complete overlap of the two populations (as seen in the 
present study, Figure 7-9), indicating that defining LGE CMR on the basis of 
visual assessment is neither sensitive nor specific for predicting endocardial 
voltage. 
More recently, a study of 11 patients undergoing repeat LA catheter ablation 
suggested a statistical difference between the mean bipolar endocardial 
voltages corresponding with LGE CMR SI thresholds of 3 to 5 SD above the 
mean SI of the atrial blood pool.166 No statistical difference was seen above 5 
SD, and the authors concluded that SI above this might represent fully scarred 
atrial myocardium. However, this would not explain the lack of statistical 
significance at 0 to 3 SD. More importantly, as demonstrated in Figure 7-7 and 
Figure 7-8, whilst there may be a trend towards lower mean voltage with 
increased CMR SI between 3 and 5 SD, the significant overlap between the 
populations means that determining a clinically useful threshold from these 
data is not possible. 
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7.4.2 Atrial endocardial voltage thresholds 
As described in the previous chapter, in current clinical practice atrial scar is 
most commonly identified by a bipolar voltage of ≤0.05 mV.25 When this 
threshold was applied in this study (in patients with previous ablation), only 
1.8% of the points were below this threshold. This further suggests that using a 
threshold of ≤0.05 mV to define atrial scar could significantly underestimate the 
extent of previous ablation injury. Whilst applying a threshold of ≤0.3 mV 
demonstrated a better visual correlation with CMR in some patients, this was 
not true for most patients (Figure 7-5). The absence of low voltage points in 
areas of LGE on the CMR reconstructions raises the possibility that CMR cannot 
distinguish between complete and incomplete scar and that the two techniques 
may be complementary, rather than interchangeable. 
7.4.3 LGE CMR prediction of electrical reconnection and isolation 
In the first of the aforementioned studies, the authors reported that “all patients 
with incomplete ablation sets marked by identifiable gap lesions had recovery 
of electrical activity on repeat electrophysiological study,” suggesting that LGE 
CMR was able to predict electrical reconnection in all 13 patients.82  
However, in the second study, the authors found no appreciable relationship 
between sites of PV reconnection and ‘gaps’ on the LGE CMR images. They 
found completely circumferential enhancement on LGE CMR in only two out of 
37 PVs and PV reconnection sites were frequently seen in regions of scar.  
The results of the present study agree with the latter. As low SI on LGE CMR 
would be the most likely sites of reconnection and low SI were seen in all 
lesions (whether electrically isolated or not), this would suggest that LGE CMR 
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cannot currently predict electrical integrity with a clinically useful sensitivity or 
specificity. However, this finding is unsurprising, as it is known that PV isolation 
can occur with an incompletely circumferential ablation lesion and, equally, 
electrical reconnection may be due to small strands of intact atrial myocytes, 
well beyond the resolution of any non-invasive imaging technique or even 
invasive endocardial voltage mapping.171, 172 In this study, only six patients had 
previously undergone LA roof line ablation, and only four of these remained 
blocked. Five patients had previously undergone mitral line ablation, and only 
three of these remained blocked. The small sample sizes indicate that these 
results should be interpreted with caution. 
7.4.4 Limitations 
There are several reasons why a linear relationship between LGE CMR SI and 
endocardial voltage might not be expected. These can be divided into factors: 1) 
related to the LGE acquisition itself; 2) related to the recording of endocardial 
voltage; 3) related to the comparison of the two datasets.  
1) Unlike computed tomography, with conventional LGE imaging sequences, SI 
is expressed on an arbitrary scale that differs from one imaging study to 
another and is not necessarily suitable for quantification between patients. 
Image contrast is generated by the difference in SI between normal and 
abnormal myocardium and is dependent upon surface coil proximity, sequence 
parameters (particularly the TI), body mass index, haematocrit, renal function, 
field strength and pharmacokinetic handling of the contrast agent. Furthermore, 
there is currently no consensus on the optimum timing of atrial LGE CMR after 
contrast administration, or on the choice and dose of contrast agent, which also 
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affect SI. As the time from contrast administration to image acquisition 
increases, the SI of the atrial blood pool progressively reduces, whilst that of 
scarred atrial myocardium increases, altering the ratio between the two 
intensities dramatically. In this study, these parameters were chosen based on 
previously published studies of atrial CMR and clinical experience. 
2) Whilst invasive atrial endocardial voltage mapping is the current clinical gold 
standard for characterising the atrial and ventricular substrate, recordings will 
depend on tissue contact (contact force assessment was not available for this 
study), catheter tip size, atrial wall thickness and far-field electrograms. In this 
study, these limitations were mitigated by collecting a large number of voltage 
points by an experienced operator using a point-by-point technique. The 
accuracy of future experiments could be improved by spring-based contact 
assessment techniques, such as SmartTouch (Biosense Webster). 
3) Point-by-point comparison of the LGE CMR SI and endocardial voltage 
requires the image registration of two differently-acquired LA shells, which will 
always include a degree of error. Iterative closest point registration was used in 
addition to the more simplistic landmark registration to reduce this error. 
Despite this, the different geometries of the CMR and endocardial voltage shells 
could have contributed to the weak point-by-point relationship. 
7.5 Conclusions 
Whilst previous studies have suggested a relationship between LGE CMR SI and 
atrial endocardial voltage,82, 165, 166 this study, in the largest and most uniform 
cohort of patients to date, demonstrates that the point-by-point correlation 
between the two parameters is very weak and that low endocardial voltage can 
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occur at sites of low and high CMR SI. Furthermore, using an objective method 
of assessing gaps in ablation lesions, LGE CMR is unable to predict electrical 
conduction. Endocardial voltage mapping and LGE CMR should be seen as 
complementary techniques for defining atrial substrate prior to repeat catheter 
ablation. These procedures have electrical, rather than anatomical, endpoints 
and both techniques should be seen as useful qualitative, rather than 
quantitative tools in assessing patients prior to repeat catheter ablation for LA 
arrhythmias. 
 
In the next chapter, the techniques used in this and the previous chapter are 
used to develop an integrative approach between CMR and interventional 
cardiac electrophysiology.  
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8 Real-time magnetic resonance-guided atrial 
electroanatomical mapping and ablation using 
active catheter tracking 
8.1 Introduction 
Over the last two decades, advances in the understanding of arrhythmia 
mechanism and catheter design have resulted in a high degree of success for the 
cure of regular narrow complex tachycardias.173 Extension of the principles and 
techniques of conventional electrophysiology (EP) to more complex 
arrhythmias such as AF, atypical LA flutters and scar-related ventricular 
tachycardia have led to significant advances in the management of these 
problems, but with more modest clinical success.52-55, 62 This is largely related to 
the technical difficulties of catheter navigation and manipulation within the 
heart using x-ray fluoroscopy alone, together with the electrophysiological 
complexity of both the arrhythmia and its anatomical substrate.  
Whilst catheter navigation has been greatly facilitated by the development of 
non-fluoroscopic EAM systems, geometries constructed by conventional EAM 
suffer inherent limitations, which, if overcome, might translate into improved 
catheter navigation and lesion delivery. There are several advantages of MR-EP 
over x-ray fluoroscopy and conventional EAM systems. It provides rapid, high 
resolution, 3D visualisation of the true anatomy and endocardial surface of the 
cardiac chambers with unrivalled soft tissue contrast, the potential to visualise 
ablation lesions and acute complications with high spatial resolution, and raises 
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the possibility of eliminating patient and physician exposure to ionising 
radiation. 
Whilst previous studies have demonstrated the feasibility of MR-EP using both 
passively152, 153, 174-178 and actively151, 178-181 tracked MR-compatible catheters, 
translation into human studies has been limited152, 153, 177, 178 and none of these 
studies has demonstrated all of the components of an MR-EP system to rival 
conventional EAM and ablation. The aim of this pre-clinical study was to 
demonstrate the feasibility of an actively-tracked, fully MR-guided system with 
activation mapping before and after irrigated RF ablation, as a prelude to a 
planned human study. 
8.2 Methods 
8.2.1 MR-compatible catheter and active tracking 
An irrigated 9F deflectable MR-EP mapping and ablation catheter (Vision MR, 
Imricor Medical Systems, Burnsville, MN) was designed for this study (Figure 
8-1). The catheter was equipped with two miniature MR receive coils, which 
allowed detection of position and orientation of the catheter tip section, and a 
fibre-optic temperature sensor. Transformer cables were used for signal 
transmission in the catheter shaft to avoid unintentional MR-induced device 
heating.182 The catheter was connected to a catheter interface module, 
comprising pre-amplifiers for the MR tracking signal and RF safety circuitry, 
which in turn was connected to a coil connector of a 1.5 Tesla MR scanner 
(Achieva, Philips Healthcare, Best, Netherlands). 
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Figure 8-1: Irrigated 9F deflectable MR-EP mapping and ablation catheter 
(Vision MR, Imricor Medical Systems, Burnsville, MN). 
 
Active tracking MR sequences were used to measure one-dimensional 
projections of the MR signal received by the miniature receive coils.145 
Subsequent projections acquired on orthogonal axes permitted the localisation 
of the coils in three dimensions, which were displayed on the image guidance 
platform (iSuite, Philips Research, Hamburg, Germany) as catheter models 
superimposed on MR image data at a rate of 10 Hz. 
8.2.2 MR-EP suite 
The MR-EP suite integrated a standard clinical 1.5 Tesla MR scanner, a patient 
monitoring system suitable for MR use (Expression, Invivo, Gainsville, FL), an 
EP recording system specifically designed for MR use (Horizon, Imricor Medical 
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Systems, Burnsville, MN), a standard clinical RF generator (IBI 1500, St. Jude 
Medical, St. Paul, MN) and a real-time image guidance platform (iSuite, Philips 
Research, Hamburg, Germany) (Figure 8-2). ECG transmission was established 
from the patient monitoring system to both the EP recording system and the 
MR scanner. This allowed for patient monitoring, activation mapping, and MR-
triggering using a single set of ECG electrodes. 
 
Figure 8-2: Diagram of the MR-EP suite, which comprises a standard clinical 
1.5 Tesla MR scanner, a patient monitoring system suitable for MR use, an 
EP recording system specifically designed for MR use, a standard clinical RF 
generator and a real-time image guidance platform. IEGM=intracardiac 
electrogram. 
 
8.2.3 iSuite image guidance platform 
The iSuite image guidance platform included a computer located in the MR 
control room with a custom software application, a software patch for the MR 
scanner, and an MR-conditional foot pedal located next to the scanner. The 
 156 
iSuite computer was connected to the MR scanner and the screen output of the 
computer was repeated on a monitor next to the scanner. A foot pedal was 
connected to the computer via a cable equipped with filters to remove RF noise 
and maintain MR image quality. All functions of the iSuite could be controlled 
from the computer, with simultaneous control of the imaging mode (real-time 
imaging or active catheter tracking) via the foot pedal. The iSuite provided 
visualisation of 3D datasets (by multi-planar reformatting of 2D slices in user-
defined orientations or by surface models created by segmentation of 
anatomical structures) together with real-time MR image slices and the position 
of the tip section of the Imricor Vision Ablation Catheter.  
8.2.4 Animal model and protocol 
In five female Danish Landrace pigs, under general anaesthesia, as described in 
section 5.1.1 (page 77), two 9F sheaths were placed percutaneously in the right 
femoral vein, followed by a bolus intravenous injection of 100 IU/kg heparin.  
The five pigs underwent pre-ablation T2W and 3D b-SSFP CMR as described in 
section 5.4 (page 83), followed by activation mapping and ablation according to 
the protocol described below. The animals then immediately underwent post-
ablation T2W CMR and post-ablation activation mapping, before they were 
euthanised with an intravenous bolus of phenobarbital (80 mg/kg).  
It was not possible to perform RF ablation in a sixth animal due to a technical 
fault with the RF generator and this animal was, therefore, excluded from the 
study. 
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8.2.5 Electroanatomical mapping and ablation 
The entire procedure was performed in the MR scanner without fluoroscopy. 
First, active catheter tracking was used to place one Vision MR catheter in the 
CS and to advance a second Vision MR catheter to the RA.  
The RA from the 3D b-SSFP acquisition was manually segmented using freely 
available 3D medical image segmentation software (itk-SNAP Version 2.2.0) and 
the shell imported into iSuite to act as a roadmap for mapping and ablation. As 
the RA catheter was moved, the actively tracked catheter position was projected 
on to this shell and the multi-planar reformat of the 3D b-SSFP (axial, sagittal 
and coronal views) was automatically updated to show the relevant views 
(Figure 8-3). 
Activation data was acquired during CS pacing. For each sampling point, the 
time delay from the pacing artifact to the local RA electrogram was measured 
on the EP recording system and automatically transmitted to the image 
guidance platform to produce a colour-coded activation map on the RA shell. 
Point-by-point RF ablation (35 W, 48oC, 60 s per lesion, 17 ml/min irrigation) 
was then performed from the SVC to the IVC along the posterior wall of the RA 
and the location of each ablation point recorded on the RA shell. The foot pedal 
was used to allow rapid switching from active catheter tracking (for catheter 
navigation) to real-time imaging (to confirm the tracked catheter position 
before each RF delivery).  
Following completion of the intercaval ablation lesion and post-ablation MR, the 




Figure 8-3: A screenshot from the iSuite image guidance platform. As the 
catheters (green and yellow=coronary sinus catheter; red and yellow=RA 
catheter) were moved, the actively tracked catheter positions were 
projected on to the segmented RA shell (bottom right) and the multi-planar 
reformat of the 3D b-SSFP was automatically updated to show the relevant 
views (top left – sagittal; top right – coronal; bottom left – axial). Red circles 
indicate the site of ablation points. 
 
8.2.6 Macroscopic and microscopic examination 
After the animals were euthanised, the hearts were explanted for macroscopic 
and microscopic examination as described in section 5.3 (page 79). 
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8.2.7 Preliminary studies and troubleshooting 
Over a three year period prior to the experiments described in this chapter, a 
series of animal experiments (20 pigs) were performed to test and troubleshoot 
the individual components of the MR-EP system described in this chapter, 
initially using a prototype catheter. These experiments involved multiple 
iterations of the catheter design, iSuite image guidance platform, Horizon EP 
recording system and workflow efficiency. Ex-vivo safety testing of the various 
components were performed by the individual manufacturers and are not 
reported in this chapter. 
8.3 Results 
8.3.1 Catheter navigation and function 
Using active catheter tracking, the two Vision MR catheters were easily 
positioned in the CS and RA in all animals, without the need for fluoroscopy 
(Figure 8-3). Thereafter, high-fidelity electrograms could be recorded by both 
catheters with minimal MR interference (Figure 8-4), and atrial capture during 
RA and CS pacing was seen in all animals (Figure 8-4). As the RA mapping 
catheter was moved around the chamber during active tracking, its position 
was updated on the 3D RA shell and the three-view 3D b-SSFP multi-planar 
reformat automatically updated according to the catheter location. 
Irrigated RF ablation was successfully performed in all five animals, although 
two of the five SVC-IVC lines were macroscopically incomplete. The tracked 
catheter position was verified by real-time imaging prior to each ablation 
delivery (Figure 8-5).  
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Figure 8-4: Surface ECG (white) and intracardiac electrograms from the RA 
(blue) and CS (yellow) catheters. The top trace is during sinus rhythm, 
whilst the bottom trace is during CS pacing at 100 beats per minute. 
 
 
Figure 8-5: Real-time sagittal MR image confirming the red tracked catheter 
tip position as a signal void. 
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Figure 8-6: Sagittal T2W MR image following intercaval ablation 
demonstrating enhancement along the ablation line (arrows). 
 
8.3.2 Pre- and post-ablation T2-weighted MR 
All animals underwent pre- and post-ablation T2W MR. No appreciable pre-
ablation T2W enhancement was seen in any of the animals, but was seen 
between the SVC and IVC in all animals post-ablation (Figure 8-6). 
8.3.3 Electroanatomical mapping 
The RA on the 3D b-SSFP MR acquisition was successfully segmented in all 
animals. This was then imported into the iSuite image guidance platform to act 
as the shell for EAM. Using active tracking, activation maps (mean number of 
points 34 ± 5; mean duration 20 ± 8 minutes) during CS pacing were created in 
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all animals, both before and after ablation. In one of the animals there was a 
change in the pattern of activation of the RA following ablation (Figure 8-7), 
with an activation detour around the linear ablation lesion, as seen in Chapter 6. 
However, in the other animals it was not possible to demonstrate an activation 
detour (Figure 8-8).  
 
Figure 8-7: Left column – iSuite pre-ablation (top row) and post-ablation 
(bottom row) activation maps during coronary pacing, demonstrating an 
activation detour following intercaval ablation. Green points indicate 
mapping points; red points indicate ablation points. Right column - example 
Carto activation maps from Figure 6-4 are shown for comparison. 
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Figure 8-8: Pre-ablation (top row) and post-ablation (bottom row) 
activation maps of the RA during CS pacing in (from left to right) 
anteroposterior, left lateral, posteroanterior and right lateral views. Green 
points indicate mapping points. 
 
8.3.4 Macroscopic and microscopic pathology 
Macroscopic photographs of a linear ablation lesion immediately after heart 
explantation, together with the corresponding iSuite 3D RA shell showing the 
intended location of ablation, are shown in Figure 8-9. A quantitative 
comparison of the ablation points on iSuite with the pathological specimens was 
not performed. Macroscopic photographs of all five ablation lines, after fixation 
in formaldehyde, are shown in Figure 8-10. 
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Figure 8-9: Left – macroscopic view of the opened RA, with the SVC at the top 
of the image and the IVC at the bottom of the image. The ablation line is seen 
on the posterior wall of the RA (arrows). Right – 3D anatomical shell from 





Figure 8-10: Macroscopic photographs of the ablation lines after fixation in 
formaldehyde.  
 
A macroscopic cross section through the ablation line (showing the typical 
features of RF injury – a central zone of pallor and a surrounding hemorrhagic 
border zone) and microscopic sections (stained with hematoxylin and eosin) 
are shown in Figure 8-11. Microscopic examination demonstrated findings 
consistent with RF ablation: transmural coagulative necrosis, haemorrhage, 
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interstitial oedema, disruption of myofiber structure and increased cytoplasmic 
eosinophilia. 
 
Figure 8-11: A - tissue slice cut perpendicular to the ablation line shows 
transmural injury. Scale bar 5 mm. B - border zone between ablated and 
spared atrial wall (marked with dashed box in A). Hematoxylin-eosin stain. 
Scale bar 250 µm. C - higher magnification of ablated tissue (marked with * 
in A) shows coagulative necrosis with disruption of myofiber structure, 




All five animals survived until the end of the procedure and there was no 
evidence of cardiac perforation, pericardial effusion or cardiac tamponade in 
any of the animals. Three of the animals developed AF during the procedure – 
this self-terminated in one animal and required intravenous flecainide (50mg) 
in the other two. There were no ventricular arrhythmias. 
8.4 Discussion 
This study was designed to show the feasibility and safety of a fully MR-guided 
EP system that would be suitable for use in human studies. All of the steps 
necessary for RA ablation were demonstrated: real-time catheter navigation, 
pacing, irrigated linear RF ablation and pre- and post-ablation imaging and 
activation mapping. However, this was a preliminary study with several 
limitations. 
8.4.1 Technical challenges of MR-EP 
Previous studies investigating the potential of MR-EP have focused on the 
feasibility of performing EP studies and limited RF ablation in an MR 
environment.151-153, 174-181 However, the many technical challenges of 
performing MR-EP procedures explains why, despite the first description of 
MR-EP in 2000,138 its uptake in human use has been limited to either EP studies 
alone (without ablation)153 or to an isolated case report of cavotricuspid 
isthmus ablation.177  
One of the principle limitations to clinical use of MR in interventional EP 
remains the availability of clinical-grade MR-compatible catheters. Currently 
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available MR-compatible catheters rely on either passive or active tracking for 
visualisation. Passive tracking (used in the two aforementioned human 
studies153, 177) uses magnetic susceptibility artifacts or signal voids created by 
the catheter tip, whilst active tracking (used in this study) requires the creation 
of a signal that is actively detected by a catheter tip RF coil, in order to identify 
its location. However, the coil needs to be connected to the scanner with a 
conductive wire and rapidly changing magnetic and electrical fields can result 
in substantial local heating, which would be unsafe for clinical use. The custom-
designed transformer-based transmission lines used in the catheter in this 
study have been previously shown to undergo negligible RF- and pacing-
induced resistive heating in safety testing.182  
Furthermore, additional wires equipped with inductive and resonant elements 
allow the recording of high-fidelity intracardiac electrograms. No MR imaging 
was performed during recording of intracardiac electrograms in this study. 
However, MR-induced artefacts on electrograms can be suppressed efficiently 
by filtering.178, 180 Pacing was also successfully performed via these wires with a 
standard clinical stimulator.  
8.4.2 MR-guided electroanatomical mapping 
Only two of the previous MR-EP studies (both from the same group) have 
demonstrated MR-guided EAM,180, 181 which would be required if MR-EP is to 
replace conventional x-ray fluoroscopy and EAM-guided complex ablation. 
However, these studies only demonstrated voltage mapping of the LV180 and of 
a limited portion of the LA.181 This study, for the first time, demonstrated 
activation mapping of the entire RA using active tracking and automatic transfer 
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to the image guidance system to form a colour-coded shell, in a similar manner 
to conventional EAM systems. 
Active catheter tracking allowed accurate and fast EAM, including manoeuvring 
the catheter to each target location and recording the intracardiac electrogram 
and 3D position. Approximately 30 mapping points were recorded in 20 
minutes. In comparison, catheter manipulation using real-time MR imaging of a 
passively visualised device has been reported to require 2-5 minutes per 
mapping point.174 Based on this experience, active tracking is considered to be a 
prerequisite for MR-guided EAM. Furthermore, active tracking allows an 
intuitive 3D overview of already mapped locations in relation to catheter 
position and cardiac anatomy, similar to conventional EAM systems. 
8.4.3 Limitations 
1) It was not possible to perform RF ablation in a sixth animal due to a technical 
fault with the RF generator and this animal was, therefore, excluded from the 
study. 
2) It was only possible to demonstrate an activation detour following ablation 
in one of the animals, whereas this was seen in all animals in Chapter 6. This is 
likely to reflect the significantly lower point density of the iSuite activation 
maps (mean number of points 34 ± 5) compared with the Carto maps (mean 
number of points 545 ± 400), together with gaps in the SVC-IVC ablation lesions 
and the difficulties of demonstrating an activation change in the small tubular 
porcine RA. 
3) A quantitative comparison of the location of ablation points on iSuite with 
the pathological specimens was not performed. This was due to the deformation 
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of the RA during pathological examination and the variation in the macroscopic 
features of the ablation lesions. 
4) The aim of this study was to assess the feasibility of MR-guided ablation and 
EAM, and whilst T2W images were acquired before and after ablation, lesion 
assessment by MR was not the focus of this study. With the present MR-EP 
system, it was possible to visualise lesion formation immediately after, but not 
during, lesion formation. This contrasts with other emerging RF-catheter 
technologies such as optical coherence tomography183 and ultrasound,184 which 
have the ability to visualise lesion formation in real-time. 
8.5 Conclusions 
MR-guided EAM and ablation using active catheter tracking is safe and feasible 
in an animal model and the MR-EP setup provides an efficient workflow. 
Catheters show good localisation accuracy and intra-cardiac signal quality in 
vivo and allow for pacing and ablation using standard RF equipment. Combined 
with intraprocedural lesion imaging, MR-EP has the potential to significantly 
improve the way current ablation procedures are performed. 
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9 Conclusion 
The overall aim of this thesis was to validate CMR of the atrial wall and to 
demonstrate its utility in MR-EP, using both pre-clinical animal and clinical 
human studies. There were three main objectives: 
1) To provide a histological validation of CMR and EAM of acute and chronic 
ablation injury in an animal model of atrial ablation. 
2) To compare atrial CMR findings with endocardial voltage mapping in patients 
undergoing repeat catheter ablation for LA arrhythmias and assess the ability of 
atrial CMR to predict gaps in ablation lesions. 
3) To demonstrate the feasibility of an actively-tracked, fully MR-guided system 
with activation mapping before and after irrigated RF ablation, as a prelude to a 
future human study. 
9.1 Original contributions 
1) Whilst LGE CMR of acute and chronic ventricular myocardial injury has been 
validated pathologically, this has never been demonstrated in the atrium. This is 
despite several recent studies suggesting a role for atrial LGE CMR in assessing 
patient suitability and response to catheter ablation of AF.51, 77-80, 82-85, 87 Chapter 
6 presents the first histopathological validation of CMR to define acute and 
chronic atrial ablation injury, including CMR SI thresholds that best match 
histological lesion volumes. However, the wide range of individual SI thresholds 
across the animals suggests that these values should be applied with caution. 
 172 
2) Invasive atrial endocardial voltage mapping, the current clinical gold 
standard for characterising the atrial substrate, has not been pathologically 
validated or systematically compared with CMR findings. Voltage thresholds in 
common clinical use have been extrapolated from ventricular studies 
comparing EAM with post-myocardial infarction scar155, 156 and not ablation-
induced injury. Chapter 7 presents endocardial voltage thresholds to define 
acute and chronic atrial ablation injury, which challenge values currently used 
in clinical practice. 
3) Previous small studies have suggested a qualitative82 and quantitative165, 166 
relationship between areas of LGE and areas of low endocardial voltage in 
patients undergoing repeat catheter ablation. However, there is controversy 
regarding the reproducibility and diagnostic ability of atrial LGE CMR.167 
Chapter 7 demonstrates in the largest and most uniform cohort of patients to 
date that the point-by-point correlation between the two parameters is very 
weak, and that low endocardial voltage can occur at sites of low and high LGE 
CMR SI. Whilst it is certainly possible to demonstrate areas of high LGE CMR SI 
in the same location as areas of low endocardial voltage (and vice versa), the 
sensitivity and specificity are poor.  
4) There is also conflicting evidence regarding the ability of LGE CMR to predict 
the electrical integrity of chronic ablation lesions. One study demonstrated that 
LGE CMR was able to predict electrical reconnection by identifying gaps in 
ablation lesions,82 whilst in another the opposite was found.165 However, these 
studies used subjective thresholding to distinguish between normal and 
abnormal atrial tissue, and, therefore, the presence or absence of gaps. A lower 
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threshold would have resulted in more ‘scar’, whereas a higher threshold would 
have resulted in more ‘gaps’. Using an objective method of assessing gaps in 
ablation lesions, Chapter 7 shows that LGE CMR is unable to reliably predict 
electrical conduction.  
5) Whilst previous studies have demonstrated the feasibility of MR-EP using 
both passively152, 153, 174-178 and actively151, 178-181 tracked MR-compatible 
catheters, translation into human studies has been limited152, 153, 177, 178 and 
none of these studies has demonstrated all of the components of an MR-EP 
system to rival conventional EAM and ablation. Chapter 8 demonstrates the 
feasibility of performing all of the steps necessary for RA ablation using an 
actively-tracked fully MR-guided system with activation mapping before and 
after irrigated RF ablation. 
9.2 Implications and limitations 
Despite the promise of early studies on atrial CMR, its clinical use has remained 
limited, primarily due to technical difficulties in image acquisition and 
consequent concerns regarding interpretation and reproducibility of the 
findings. Chapter 6 demonstrates that high LGE CMR SI does represent fibrous 
scar in the atrium eight weeks after ablation, suggesting that the technique can 
be used to define chronic atrial scar, at least qualitatively. Application of the 
LGE CMR SI thresholds presented in this chapter might allow a quantitative 
non-invasive assessment of the underlying atrial substrate before repeat 
catheter ablation for atrial arrhythmias. However, the wide range of individual 
SI thresholds across the animals suggests that these values should be applied 
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cautiously and that larger numbers would be needed to define these more 
accurately. 
The results in Chapter 7 suggest that these findings may not readily translate to 
human LA ablation. This is likely to reflect the difficulties of imaging 
anatomically complex LA ablation (involving circumferential, linear and point 
ablation), compared with the single linear lesion performed in the RA animal 
model, or may suggest that low voltages occur at sites that do not enhance with 
LGE CMR and vice versa. 
These findings have to be borne in mind when considering the potential of MR-
EP. Whilst Chapter 8 demonstrates that MR-guided ablation and EAM is safe 
and feasible in an animal model, a more accurate quantitative assessment of 
atrial wall injury (particularly lesion transmurality) is necessary if MR-guided 
ablation is to achieve its principle advantage over conventional x-ray 
fluoroscopy.  
9.3 Future directions 
The findings and techniques developed in this thesis will be used for a human 
study of catheter ablation of typical right atrial flutter under MR guidance, 
performed in a hybrid XMR facility. This study will assess the safety and efficacy 
of using the MR-EP system described in Chapter 8. Fifteen patients undergoing 
first-time clinically-indicated ablation for typical atrial flutter will be recruited 
to the study.  
Under general anaesthetic, the patient will be connected to the MR-EP system as 
described in Chapter 8 and two 9F sheaths will be inserted into the right 
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femoral vein. Pre-ablation b-SSFP CMR will then be performed. Active catheter 
tracking will be used to place one Vision MR catheter in the CS and to advance a 
second Vision MR catheter to the RA. The RA from the b-SSFP acquisition will be 
manually segmented and the shell imported into iSuite to act as a roadmap for 
mapping and ablation. An activation map of the RA during CS pacing will be 
created using the RA catheter.  
The RA catheter will then be positioned at the ventricular end of the 
cavotricuspid isthmus and RF ablation will be performed point-by-point along 
the isthmus. Active catheter tracking will be used to position the catheter, with 
real-time imaging used for confirmation before each RF delivery. The 
procedural endpoint will be the demonstration of bidirectional conduction 
block across the cavotricuspid isthmus.  
A post-ablation activation map of the RA will then be created during CS pacing. 
Post-ablation T2W and LGE CMR will then be performed, before the sheaths are 
removed and the patient recovered from general anaesthesia. Patients will be 
followed-up after three months with a repeat CMR study, a 24-hour ECG 
recording and a clinical review. 
However, the real potential of MR-EP is in the treatment of more complex 
arrhythmias such as AF, atypical LA flutters and scar-related ventricular 
tachycardia. In order to realise this potential, several future developments and 
studies will be required. First, and foremost, the acute CMR findings that predict 
long-term, durable ablation lesions need to be defined. Whilst previous studies 
have investigated atrial CMR within one hour157 and 24 hours51 of AF ablation, 
these predictive findings need to be assessed during the procedure, so that 
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further ablation lesions can be applied as necessary. This would best be 
demonstrated through further longitudinal animal studies. Sequence 
development, target-specific contrast agents and improvements in CMR 
resolution are likely over the next few years and may help to make MR-EP a 
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